

4311



Consommation et
Affaires commerciales Canada

Consumer and
Corporate Affairs Canada

Bureau des brevets

Patent Office

Ottawa, Canada
K1A 0C9

(21) (A1) 2,091,102
(22) 1993/03/05
(43) 1993/09/07

(51) INTL. CL. ⁵ C12N-015/12; C12Q-001/68; C07K-013/00; C07K-015/12;
C07H-021/04; G01N-001/68

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) Microsomal Triglyceride Transfer Protein

(72) Wetterau, John R., II - ;
Sharp, Daru Y. - ;
Gregg, Richard E. - ;

(73) Same as inventor

(30) (US) 847,503 1992/03/06

(57) 32 Claims

Notice: This application is as filed and may therefore contain an
incomplete specification.

Canada

CCA 3764 (10-87) et 7630 71-826-3764

2091102

DC21a

Abstract

MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN

Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention additionally concerns novel methods for lowering serum lipid levels and therapeutic agents having such activity.

MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN

5 Cross-Reference to Related Application

This is a continuation-in-part of U. S. patent application Ser. No. 847, 503, filed March 6, 1992.

10 Field of the Invention

This invention relates to microsomal triglyceride transfer protein, genes for the protein, expression vectors comprising the genes, host cells comprising the vectors, methods for producing the protein, methods for detecting inhibitors of the protein, and methods of using the protein and/or its inhibitors.

15

Background of the Invention

The microsomal triglyceride transfer protein (MTP) catalyzes the transport of triglyceride (TG), cholesteryl ester (CE), and phosphatidylcholine (PC) between small unilamellar vesicles (SUV). Wetterau & Zilversmit, Chem. Phys. Lipids 38, 205-22 (1985). When transfer rates are expressed as the percent of the donor lipid transferred per time, MTP expresses a distinct preference for neutral lipid transport (TG and CE), relative to phospholipid transport. The protein from bovine liver has been isolated and characterized. Wetterau & Zilversmit, Chem. Phys. Lipids 38, 205-22 (1985). Polyacrylamide gel electrophoresis (PAGE) analysis of the purified protein suggests that the transfer protein is a complex of two subunits of apparent molecular weights 58,000 and 88,000, since a single band was present when purified MTP was electrophoresed under nondenaturing condition,

while two bands of apparent molecular weights 58,000 and 88,000 were identified when electrophoresis was performed in the presence of sodium dodecyl sulfate (SDS). These two polypeptides are hereinafter referred to as 58 kDa and 88 kDa, respectively, or the 58 kDa and the 88 kDa component of MTP, respectively, or the low molecular weight subunit and the high molecular weight subunit of MTP, respectively.

Characterization of the 58,000 molecular weight component of bovine MTP indicates that it is the previously characterized multifunctional protein, protein disulfide isomerase (PDI). Wetterau *et al.*, *J. Biol. Chem.* 265, 9800-7 (1990). The presence of PDI in the transfer protein is supported by evidence showing that (1) the amino terminal 25 amino acids of the bovine 58,000 kDa component of MTP is identical to that of bovine PDI, and (2) disulfide isomerase activity was expressed by bovine MTP following the dissociation of the 58 kDa - 88 kDa protein complex. In addition, antibodies raised against bovine PDI, a protein which by itself has no TG transfer activity, were able to immunoprecipitate bovine TG transfer activity from a solution containing purified bovine MTP.

PDI normally plays a role in the folding and assembly of newly synthesized disulfide bonded proteins within the lumen of the endoplasmic reticulum. Bulleid & Freedman, *Nature* 335, 649-51 (1988). It catalyzes the proper pairing of cysteine residues into disulfide bonds, thus catalyzing the proper folding of disulfide bonded proteins. In addition, PDI has been reported to be identical to the beta subunit of human prolyl 4-hydroxylase. Koivu *et al.*, *J. Biol. Chem.* 262, 6447-9 (1987). The role of PDI in the bovine transfer protein is not clear. It does appear to be an essential component of the transfer protein as dissociation of PDI from the 88 kDa component of bovine MTP by either low concentrations of a denaturant (guanidine HCl), a chaotropic agent (sodium perchlorate), or a nondenaturing detergent (octyl glucoside) results in a loss of transfer activity. Wetterau *et al.*

Biochemistry 30, 9728-35 (1991). Isolated bovine PDI has no apparent lipid transfer activity, suggesting that either the 88 kDa polypeptide is the transfer protein or that it confers transfer activity to the protein complex.

- 5 The tissue and subcellular distribution of MTP activity in rats has been investigated. Wetterau & Zilversmit, Biochem. Biophys. Acta 875, 610-7 (1986). Lipid transfer activity was found in liver and intestine. Little or no transfer activity was found in plasma, brain, heart, or kidney. Within the liver, MTP was a soluble protein
10 located within the lumen of the microsomal fraction. Approximately equal concentrations were found in the smooth and rough microsomes.

- Abetalipoproteinemia is an autosomal recessive disease characterized by a virtual absence of plasma lipoproteins which
15 contain apolipoprotein B (apoB). Kane & Havel in The Metabolic Basis of Inherited Disease, Sixth edition, 1139-64 (1989). Plasma TG levels may be as low as a few mg/dL, and they fail to rise after fat ingestion. Plasma cholesterol levels are often only 20-45 mg/dL. These abnormalities are the result of a genetic defect in
20 the assembly and/or secretion of very low density lipoproteins (VLDL) in the liver and chylomicrons in the intestine. The molecular basis for this defect has not been previously determined. In subjects examined, triglyceride, phospholipid, and cholesterol synthesis appear normal. At autopsy, subjects are free
25 of atherosclerosis. Schaefer et al., Clin. Chem. 34, 89-12 (1988). A link between the apoB gene and abetalipoproteinemia has been excluded in several families. Talmud et al., J. Clin. Invest. 82, 1803-6 (1988) and Huang et al., Am. J. Hum. Genet. 46, 1141-8 (1990).

- 30 Subjects with abetalipoproteinemia are afflicted with numerous maladies. Kane & Havel, supra. Subjects have fat malabsorption and TG accumulation in their enterocytes and hepatocytes. Due to the absence of TG-rich plasma lipoproteins, there is a defect in the transport of fat-soluble vitamins such as

vitamin E. This results in acanthocytosis of erythrocytes, spinocerebellar ataxia with degeneration of the fasciculus cuneatus and gracilis, peripheral neuropathy, degenerative pigmentary retinopathy, and ceroid myopathy. Treatment of abetalipoproteinemic subjects includes dietary restriction of fat intake and dietary supplementation with vitamins A, E and K.

To date, the physiological role of MTP has not been demonstrated. *In vitro*, it catalyzes the transport of lipid molecules between phospholipid membranes. Presumably, it plays a similar role *in vivo*, and thus plays some role in lipid metabolism. The subcellular (lumen of the microsomal fraction) and tissue distribution (liver and intestine) of MTP have led to speculation that it plays a role in the assembly of plasma lipoproteins, as these are the sites of plasma lipoprotein assembly. Wetterau & Zilversmit, Biochem. Biophys. Acta **875**, 610-7 (1986). The ability of MTP to catalyze the transport of TG between membranes is consistent with this hypothesis, and suggests that MTP may catalyze the transport of TG from its site of synthesis in the endoplasmic reticulum (ER) membrane to nascent lipoprotein particles within the lumen of the ER.

Olofsson and colleagues have studied lipoprotein assembly in HepG2 cells. Bostrom *et al.*, J. Biol. Chem. **263**, 4434-42 (1988). Their results suggest small precursor lipoproteins become larger with time. This would be consistent with the addition or transfer of lipid molecules to nascent lipoproteins as they are assembled. MTP may play a role in this process. In support of this hypothesis, Howell and Palade, J. Cell Biol. **92**, 833-45 (1982), isolated nascent lipoproteins from the hepatic Golgi fraction of rat liver. There was a spectrum of sizes of particles present with varying lipid and protein compositions. Particles of high density lipoprotein (HDL) density, yet containing apoB, were found. Higgins and Hutson, J. Lipid Res. **25**, 1295-1305 (1984), reported lipoproteins isolated from Golgi were consistently larger than those from the endoplasmic reticulum, again suggesting the

assembly of lipoproteins is a progressive event. However, there is no direct evidence in the prior art demonstrating that MTP plays a role in lipid metabolism or the assembly of plasma lipoprotein.

5 **Summary of the Invention**

 The present invention concerns an isolated nucleic acid molecule comprising a nucleic acid sequence coding for all or part of the high molecular weight subunit of MTP and/or Intron, 5', or 3' flanking regions thereof. Preferably, the nucleic acid molecule is a
10 DNA (deoxyribonucleic acid) molecule, and the nucleic acid sequence is a DNA sequence. Further preferred is a nucleic acid having all or part of the nucleotide sequence as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with
15 7 and 8.

 The present invention also concerns a nucleic acid molecule having a sequence complementary to the above sequences and/or Intron, 5', or 3' flanking regions thereof.

 The present invention further concerns expression vectors
20 comprising a DNA sequence coding for all or part of the high molecular weight subunit of MTP.

 The present invention additionally concerns prokaryotic or eukaryotic host cells containing an expression vector that comprises a DNA sequence coding for all or part of the high
25 molecular weight subunit of MTP.

 The present invention additionally concerns polypeptide molecules comprising all or part of the high molecular weight subunit of MTP. Preferably, the polypeptide is the high molecular weight subunit of human MTP or the recombinantly produced high
30 molecular weight subunit of bovine MTP.

 The present invention also concerns methods for detecting nucleic acid sequences coding for all or part of the high molecular weight subunit of MTP or related nucleic acid sequences.

The present invention further concerns methods for detecting an inhibitor of MTP.

The present invention further concerns a novel method for treatment of atherosclerosis, or for lowering the level of serum lipids such as serum cholesterol, TG, PC, or CE in a mammalian species comprising administration of a therapeutically effective amount of an agent that decreases the activity or amount of MTP. Such agents would also be useful for treatment of diseases associated or affected by serum lipid levels, such as pancreatitis, hyperglycemia, obesity and the like.

Brief Description of the Drawings

Figure 1 shows bovine cDNA clones. The five bovine cDNA inserts are illustrated. The continuous line at the top of the figure represents the total cDNA sequence isolated. Small, labeled bars above this line map peptide and probe sequences. The open reading frame is indicated by the second line, followed by ** corresponding to 3' noncoding sequences. Clone number and length are indicated to the left of each line representing the corresponding region of the composite sequence. Clones 64 and 76 were isolated with probe 2A, clones 22 and 23 with probe 37A and clone 2 with probe 19A. Eco RI linkers added during the cDNA library construction contribute the Eco RI restriction sites at the 5' and 3' ends of each insert. The internal Eco RI site in inserts 22 and 76 is encoded by the cDNA sequence. The Nhe I restriction site was utilized in preparing probes for isolation of human cDNA clones (below). The arrows under each insert line indicate individual sequencing reactions.

Figure 2 shows TG transfer activity in normal subjects. Protein-stimulated transfer of ^{14}C -TG from donor SUV to acceptor SUV was measured in homogenized intestinal biopsies obtained from five normal subjects. The results are expressed as the percentage of donor TG transferred per hour as a function of homogenized intestinal biopsy protein.

Figure 3 shows TG transfer activity in abetalipoproteinemic subjects. Protein-stimulated transfer of ^{14}C -TG from donor SUV to acceptor SUV was measured in homogenized intestinal biopsies obtained from four abetalipoproteinemic subjects. The results are expressed as the percentage of donor TG transferred/hour as a function of homogenized intestinal biopsy protein.

Figure 4 shows TG transfer activity in control subjects. Protein stimulated transfer of ^{14}C -TG from donor SUV to acceptor SUV in homogenized intestinal biopsies were obtained from three control subjects, one with chylomicron retention disease (open circles), one with homozygous hypobetalipoproteinemia (solid circles), and one non-fasted (x). The results are expressed as the percentage of donor TG transferred/hour as a function of homogenized intestinal biopsy protein.

Figure 5 shows western blot analysis of MTP in normal subjects. An aliquot of purified bovine MTP (lane 1) or the post 103,000 x g proteins following deoxycholate treatment of 23 μg of homogenized intestinal biopsies from 3 normal subjects (lanes 2-4) were fractionated by SDS-PAGE and then transferred to nitrocellulose. The blots were probed with anti-88 kDa.

Figure 6 shows western blot analysis of MTP in control subjects. An aliquot of purified bovine MTP (lane 1) or the post 103,000 x g proteins following deoxycholate treatment of 15 μg , 25 μg , and 25 μg homogenized intestinal biopsies from a subject with chylomicron retention disease (lane 2), a subject with homozygous hypobetalipoproteinemia (lane 3), and a non-fasted subject (lane 4), respectively, were fractionated by SDS-PAGE and then transferred to nitrocellulose. The blots were probed with anti-88 kDa.

Figure 7 shows western blot analysis of MTP in normal subjects with affinity-purified antibodies. An aliquot of purified bovine MTP (lane 1) or the post 103,000 x g proteins following deoxycholate treatment of 34 μg (lane 2) or 25 μg (lane 3) of homogenized intestinal biopsies from 2 normal subjects were

fractionated by SDS-PAGE and then transferred to nitrocellulose. The blots were probed with affinity purified anti-88 kDa.

Figure 8 shows western blot analysis of MTP in abetalipoproteinemic subjects. An aliquot of purified bovine MTP (lane 1) or post 103,000 x g proteins following deoxycholate treatment of 18 μ g (lane 2), 23 μ g (lane 3), 23 μ g (lane 4), 23 μ g (lane 5) of homogenized intestinal biopsies from four different abetalipoproteinemic subjects were fractionated by SDS-PAGE and then transferred to nitrocellulose. In lanes 6 and 7, 100 μ g of the whole intestinal homogenate (subjects corresponding in lane 4 and 5) was fractionated by SDS-PAGE and transferred to nitrocellulose. The blots were probed with anti-88 kDa.

Figure 9 shows a Southern blot analysis of a gene defect in an abetalipoproteinemic subject. Ten μ g of genomic DNA from a control, the abetalipoproteinemic subject (proband), and from the subject's mother and father were cut to completion with Taq I, electrophoresed on 1% agarose and transferred to nitrocellulose. Southern hybridization was performed using exon 13 cDNA as a probe. Two hybridizing bands in the normal lane indicated the presence of a Taq I site in the normal exon 13. One hybridizing band in the abetalipoproteinemic subject lane demonstrated the absence of this restriction sequence in both alleles in exon 13, confirming a homozygous mutation in this subject. The heterozygous state in the mother and father is shown by the three hybridizing bands, corresponding to both the normal and the mutant restriction patterns.

Figure 10 shows inhibition in MTP-catalyzed transport of TG from donor SUV to acceptor SUV by compound A described hereinafter. Compound A was dissolved in DMSO and then diluted into 15/40 buffer. Aliquots were added to a lipid transfer assay to bring the compound to the indicated final concentrations. DMSO concentration in the assay never exceeded 2 μ L/500 μ L, a concentration that was independently determined to have minimal effect on the assay. MTP-catalyzed lipid transport was measured

for 30 minutes at 37°C. TG transfer was calculated and compared to a control assay without inhibitor. Three independent assay conditions were used to demonstrate MTP inhibition by compound A. Assay conditions were: 8 nmol donor PC, 48 nmol acceptor PC, and 75 ng MTP (open circles); 24 nmol donor PC, 144 nmol acceptor PC, and 100 ng MTP (solid circles); 72 nmol donor PC, 432 nmol acceptor PC, and 125 ng MTP (open squares).

Figure 11 shows the dose response of Compound A on ApoB, ApoA1 and HSA secretion from HepG2 cells. HepG2 cells were treated with compound A at the indicated doses for 16 hours. The concentration in the cell culture media of apoB, apoA1 and HSA after the incubation period was measured with the appropriate ELISA assay and normalized to total cell protein. The data shown are expressed as a percentage of the control (DMSO only).

Figure 12 shows the effect of compound A on TG secretion from HepG2 cells. HepG2 cells were treated with Compound A at the indicated doses for 18 hours, the last two hours of which were in the presence of 5 μ Ci/mL 3H-glycerol. The concentration of radiolabelled triglycerides in the cell culture media was measured by quantitative extraction, followed by thin layer chromatography analysis and normalization to total cell protein. The data shown are expressed as a percentage of the control (DMSO only).

Figure 13 shows inhibition in MTP-catalyzed transport of TG from donor SUV to acceptor SUV by compound B described hereinafter. Compound B was dissolved in DMSO and then diluted into 15/40 buffer. Aliquots were added to a lipid transfer assay to bring the compound to the indicated final concentrations. DMSO concentration in the assay never exceeded 2 μ L/600 μ L, a concentration that was independently determined to have minimal effect on the assay. MTP-catalyzed lipid transport was measured for 30 minutes at 37°C. TG transfer was calculated and compared to a control assay without inhibitor. Two independent assay conditions were used to demonstrate MTP inhibition by compound

B. Assay conditions were: 24 nmol donor PC, 144 nmol acceptor PC, and 100 ng MTP (open circles); 72 nmol donor PC, 432 nmol acceptor PC, and 125 ng MTP (solid circles).

5 Figure 14 shows the dose response of compound B on ApoB, ApoA1 and HSA secretion from HepG2 cells. HepG2 cells were treated with compound B at the indicated doses for 16 hours. The concentration in the cell culture media of apoB, apoA1 and HSA after the incubation period was measured with the appropriate ELISA assay and normalized to total cell protein. The
10 data shown are expressed as a percentage of the control (DMSO only).

Detailed Description of the Invention

Definition of terms

15 The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.

The term "MTP" refers to a polypeptide or protein complex that (1) if obtained from an organism (e. g., cows, humans, etc.),
20 can be isolated from the microsomal fraction of homogenized tissue; and (2) stimulates the transport of triglycerides, cholesterol esters, or phospholipids from synthetic phospholipid vesicles, membranes or lipoproteins to synthetic vesicles, membranes, or lipoproteins and which is distinct from the cholesterol ester transfer
25 protein [Drayna et al., *Nature* 327, 632-634 (1987)] which may have similar catalytic properties. However, the MTP molecules of the present invention do not necessarily need to be catalytically active. For example, catalytically inactive MTP or fragments thereof may be useful in raising antibodies to the protein.

30 The term "modified", when referring to a nucleotide or polypeptide sequence, means a nucleotide or polypeptide sequence which differs from the wild-type sequence found in nature.

The term "related", when referring to a nucleotide sequence, means a nucleic acid sequence which is able to hybridize to an oligonucleotide probe based on the nucleotide sequence of the high molecular weight subunit of MTP.

5 The phrase "control regions" refers to nucleotide sequences that regulate expression of MTP or any subunit thereof, including but not limited to any promoter, silencer, enhancer elements, splice sites, transcriptional initiation elements, transcriptional termination elements, polyadenylation signals, translational control elements, translational start site, translational termination site, and message stability elements. Such control regions may be located in sequences 5' or 3' to the coding region or in introns interrupting the coding region.

15 The phrase "stabilizing" atherosclerosis as used in the present application refers to slowing down the development of and/or inhibiting the formation of new atherosclerotic lesions.

20 The phrase "causing the regression of" atherosclerosis as used in the present application refers to reducing and/or eliminating atherosclerotic lesions.

Use and utility

25 The nucleic acids of the present invention can be used in a variety of ways in accordance with the present invention. For example, they can be used as DNA probes to screen other cDNA and genomic DNA libraries so as to select by hybridization other DNA sequences that code for proteins related to the high molecular weight subunit of MTP. In addition, the nucleic acids of the present invention coding for all or part of the high molecular weight subunit of human or bovine MTP can be used as DNA probes to screen other cDNA and genomic DNA libraries to select by hybridization DNA sequences that code for MTP molecules from other organisms. The nucleic acids may also be used to generate primers to amplify cDNA or genomic DNA using polymerase chain reaction (PCR) techniques. The DNA

sequences of the present invention can also be used to identify adjacent sequences in the cDNA or genome; for example, those that encode the gene, its flanking sequences and its regulatory elements.

5 The polypeptides of the present invention are useful in the study of the characteristics of MTP; for example, its structure, mechanism of action, and role in lipid metabolism or lipoprotein particle assembly.

10 Various other methods of using the nucleic acids, polypeptides, expression vectors and host cells are described in detail below.

15 In carrying out the methods of the present invention, the agents that decrease the activity or amount of MTP can be administered to various mammalian species, such as monkeys, dogs, cats, rats, humans, etc., in need of such treatment. These agents can be administered systemically, such as orally or parenterally.

20 The agents that decrease the activity or amount of MTP can be incorporated in a conventional systemic dosage form, such as a tablet, capsule, elixir or injectable formulation. The above dosage forms will also include the necessary physiologically acceptable carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms
25 are preferred, although parenteral forms are quite satisfactory as well.

30 The dose administered must be carefully adjusted according to the age, weight, and condition of the patient, as well as the route of administration, dosage form and regimen, and the desired result. In general, the dosage forms described above may be administered in single or divided doses of one to four times daily.

Detailed description of specific embodiments**Nucleic acids**

The present invention concerns an isolated nucleic acid molecule comprising a nucleic acid sequence coding for all or part of the high molecular weight subunit of MTP. Preferably, the nucleic acid molecule is a DNA molecule and the nucleic acid sequence is a DNA sequence. Further preferred is a nucleic acid sequence having the nucleotide sequence as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8 or any part thereof, or a nucleic acid sequence complementary to one of these DNA sequences. In the case of a nucleotide sequence (e.g., a DNA sequence) coding for part of the high molecular weight subunit of MTP, it is preferred that the nucleotide sequence be at least about 15 sequential nucleotides in length, more preferably at least about 20 to 30 sequential nucleotides in length.

The following text shows a bovine cDNA nucleotide sequence (SEQ. ID. NO. 1), a human cDNA sequence (SEQ. ID. NO. 2), a comparison of the human and bovine cDNA sequences, the bovine amino acid sequence (SEQ. ID. NO. 3), the human amino acid sequence (SEQ. ID. NO. 4), and a comparison of the human and bovine amino acid sequences. In the sequence comparisons, boxed regions represent perfect identity between the two sequences.

2091102

DC21a

-14-

BOVINE cDNA SEQUENCE

(SEQ. ID. NO. 1)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
AAACTCACAT	ACTCCACTGA	AGTTTTTCTC	GATCGGGGCA	AAGGAAACCT	50
CCAAGACAGT	GTGGGCTACC	GAATTCATC	CAATGTGGAT	GTCGCTTTAC	100
TGTGGAGGAG	TCCTGATGGT	GATGATAACC	AACTGATCCA	AATTAGGATG	150
AAAGATGTAA	ACCTTGAAAA	TGTGAATCAA	CAGAGAGGAG	AGAAGAGCAT	200
TTTCAAGGA	AAAAAGTCAT	CTCAAATCAT	AAGAAAGGAA	AACTTGGAAG	250
CAAIGCAAAG	ACCTGTGCTC	CTTCATCTAA	TTCATGGAAA	GATCAAAGAG	300
TTCTACTCAT	ATCAAAATGA	ACCAGCAGCC	ATAGAAAATC	TCAAGAGAGG	350
CCTGGCTAGC	CTATTTCAGA	TGCAGTTAAG	CTCTGGAACT	ACCAATGAGG	400
TAGACATCTC	TGGAGATTGT	AAAGTGAOCT	ACCAGGCTCA	TCAAGACAAA	450
GTGACCAAAA	TTAAGGCTTT	GGATTATGTC	AAATAGAGA	GGGCTGGATT	500
TAOGACCOCA	CATCAGGTCT	TGGGTGTCAC	TTGGAAGCC	ACATCTGTCA	550
CTACCTATAA	GATAGAAGAC	AGCTTTGTTG	TAGCTGTGCT	CTCAGAAGAG	600
ATAOGTGCTT	TAAGGCTCAA	TTTTCTACAA	TCAATAGCAG	GCAAAATAGT	650
ATCGAGGCAG	AACTGGAGC	TGAAAACCAC	GGAAGCAAGC	GTGAGACTGA	700
AGCCAGGAAA	GCAGGTGCA	GCCATCATTA	AAGCAGTCGA	TTCAAAGTAC	750
AOGGOCATTC	CCATTGTGGG	GCAGGTCTTC	CAGACCAAGT	GCAAAGGATG	800
COCTTCTCTC	TCAGAGCACT	GGCAGTCCAT	CAGAAAACAC	CTGCAGCCTG	850
ACAAOCTCTC	CAAGGCTGAG	GCTGTGAGAA	GCTTCTGTC	CTTCATCAAG	900

2091102

DC21a

-15-

BOVINE cDNA SEQUENCE

(SEQ. ID. NO. 1, continued)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
CACCTCAGGA	CGGCAAAGAA	AGAAGAGATC	CTOCAAATTC	TAAAGGCAGA	950
AAACAAGGAA	GTACTACCCC	AGCTAGTGGA	TGCTGTCACC	TCTGCTCAGA	1000
CACCAGACTC	ATTAGAGGCC	ATTTTGGACT	TTCTGGATTT	CAAAAGCACC	1050
GAGAGGGTTA	TOCTOCAGGA	AAGGTTTCTC	TATGCTGTG	CATTGCTC	1100
ACATCCTGAT	GAAGAACTOC	TGAGAGCCCT	CATTAGTAAG	TTCAAAGGTT	1150
CTTTTGGFAG	CAATGACATC	AGAGFATCTG	TTATGATCAT	CATCGGGGCC	1200
CTGTGCAGGA	AGTTGTGICA	GAACCAAGGC	TGCAAACTGA	AAGGAGTAAT	1250
AGAAGCCAAA	AAGTTAATCT	TGGGAGGACT	TGAAAAAGCA	GAGAAAAAAG	1300
AGGACATOGT	GATGTAACTG	CTGGCTCTGA	AGAAAGGCGG	GCTTCCAGAA	1350
GGCATCCCGC	TCCTTCTGAA	GTACACAGAG	ACAGGAGAAG	GGCCCATTAG	1400
CCACCTTGCC	GCCACCACAC	TCCAGAGATA	TGATGTCCCT	TTCATAACTG	1450
ATGAGGTAAA	GAAGACTATG	AACAGGATAT	ACCACCAGAA	TCGTAAAATA	1500
CATGAAAAAA	CTGTGGGTAC	TACTGCAGCT	GCCATCATTT	TAAAAACAA	1550
TCCATCCTAC	ATGGAAGTAA	AAAACATCCT	GCTCTCTATT	GGGGAACCTC	1600
CCAAAGAAAT	GAATAAGTAC	ATGCTCTCCA	TTGTCCAAGA	CATCCTACGT	1650
TTTGAAACAC	CTGCAAGCAA	AATGGTCCGT	CAAGTTCTGA	AGGAAATGGT	1700
CGCTCATAAT	TACGATOGTT	TCTCCAAGAG	TGGGTCTCTC	TCTGCATATA	1750
CTGGCTACGT	AGAAAGGACT	TOCCATTGGG	CATCTACTTA	CAGCCTTGAC	1800

2091102

DC21a

-16-

BOVINE cDNA SEQUENCE

(SEQ. ID. NO. 1, continued)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
ATTCTTTACT	CTGGTTCCTGG	CATCTCTAAGG	AGAAGTAATC	TGAACATCTT	1850
TCAGTATATT	GAGAAACTC	CTCTTCATGG	TATCCAGGTG	GTCATTGAAG	1900
CCCAAGGACT	GGAGGCATTA	ATTGCAGCCA	CTCCTGATGA	GGGGGAAGAG	1950
AACCTTGACT	CCTATGCTGG	CTTGTCAGCT	CTCCTCTTTG	ATGTTCAAGT	2000
CAGACCTGTC	ACTTTTTTCA	AAGGGTACAG	TGATTTGATG	TOCAAAATGC	2050
TGTCAGCATC	TAGTGACCT	ATGAGTGTGG	TGAAAGGACT	TCTTCTGCTA	2100
ATAGATCATT	CCCAAGGAGCT	TCAGCTGCAA	TCTGGACTTA	AGGCCAATAT	2150
CGATGTTCAA	GGTGGTCTAG	CTATTGATA	TACAGGTGCC	ATGGAGTTTA	2200
GTCATGGTA	TGTTGAATCT	AAAACCCGAG	TGAAAATCG	GGTAAGTGTG	2250
TAAATAACTG	GTTGGCATCAC	GGTGGACTCC	TCTTTTGTGA	AAGCTGGCTT	2300
GGAAATTGGT	GCAGAAACAG	AAGCAGGCTT	GGAGTTTATC	TCCACGGTGC	2350
AGTTTTCTCA	GTACCCATTT	TTAGTTTGTG	TGCAGATGGA	CAAGGAAGAT	2400
GTTCCATACA	GGCAGTTTGA	GACAAAATAT	GAAAGGCTGT	CCACAGGCAG	2450
AGGTTACATC	TCTCGGAAGA	GAAAAGAAAG	OCTAATAGGA	GGATGTGAAT	2500
TCCCGCTGCA	CCAAGAGAAC	TCTGACATGT	GCAAGGTGGT	GTTTGCTCCT	2550
CAACCAGAGA	GCAGTTCCAG	TGGTTGGTTT	TGAAACTGAT	GGGGGCTGTT	2600
TCATTAGACT	TCATCTCGCC	AGAAGGGATA	AGACGTGACA	TGCTTAAGTA	2650
TTGCTCTCTG	AGAGCACAGT	GTTTACATAT	TTAAGGTGAT	TAAAGAGTTT	2700

2091102

DC21a

-17-

BOVINE cDNA SEQUENCE

(SEQ. ID. NO. 1, continued)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TGTAGAACGT	GATGAAAAC	CTCACATAAT	TAAGTTTGGG	CCTGAATCAT	2750
TTGAACTAC	CTACAGGGTC	ATTCTGAGOC	ACTCTATGIG	ATACTTLAGT	2800
AGCGTTCGT	TTTCTGTCAT	CTCTCTCAA	TCACATTAC	TACTGTGAAA	2850
CTAGTCTGC	CCTAAGAAGA	AACCATIGTT	TAAAAA	AAAAA	2900

2091102

DC21a

-18-

HUMAN cDNA SEQUENCE
(SEQ. ID. NO. 2)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
GTGACTCCTA	GCTGGGCACT	GGATGCAGTT	GAGGATTGCT	GGTCAATATG	50
ATTCTTCTTG	CTGTGCTTTT	TCTCTGCTTC	ATTCTCTCAT	ATTCAGCTTC	100
TGTTAAAGGT	CACACAACCTG	GTCTCTCATT	AAATAATGAC	CGGCTGTACA	150
AGCTCAOGTA	CTCCACTGAA	GTTCTTCTTG	ATCGGGGCAA	AGGAAAACCTG	200
CAAGACAGCG	TGGGCTACCG	CATTTCCTCC	AACGTGGATG	TGGCCTTACT	250
ATGGAGGAAT	CCTGATGGTG	ATGATGACCA	GTTGATCCAA	ATAACGATGA	300
AGGATGTAAA	TGTTGAAAAT	GTGAATCAGC	AGAGAGGAGA	GAAGAGCATC	350
TTCAAAGGAA	AAAGCCCATC	TAAAATAATG	GGAAAGGAAA	ACTTGGAAGC	400
TCTGCAAAGA	CCTACGCTCC	TTCATCTAAT	CCATGGAAAG	GTCAAAGAGT	450
TCTACTCATA	TCAAAATGAG	GCAGTGGCCA	TAGAAAATAT	CAAGAGAGGT	500
CTGGCTAGCC	TATTTGAGAC	ACAGTTAAGC	TCTGGAACCA	CCAATGAGGT	550
AGATATCTCT	GGAAATTGTA	AAGTGACCTA	CCAGGCTCAT	CAAGACAAAG	600
TGATCAAAAT	TAAGGCCTTG	GATTCATGCA	AAATAGCGAG	GTCTGGATTT	650
ACGACCCCAA	ATCAGGTCTT	GGGTGTCAGT	TCAAAGCTA	CATCTGTCAC	700
CACCTATAAG	ATAGAAGACA	GCTTTGTTAT	AGCTGTGCTT	GCTGAAGAAA	750
CACACAATTT	TGGACTGAAT	TTCCTACAAA	CCATTAAGGG	GAAAATAGTA	800
TOGAAGCAGA	AATTAGAGCT	GAAGACAACC	GAAGCAGGCC	CAAGATTGAT	850
GTCTGGAAAG	CAGGCTGCAG	CCATAATCAA	AGCAGTTGAT	TCAAAGTACA	900
CGGCCATTCC	CATTGTGGGG	CAGGTCTTCC	AGAGCCACTG	TAAAGGATGT	950
CCTTCTCTCT	CGGAGCTCTG	GCGGTCCAAC	AGTAATAACC	TGCAGCCTGA	1000

2091102

DC21a

-19-

HUMAN cDNA SEQUENCE
(SEQ. ID. NO. 2, continued)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
CAACCTTTCC	AAGGCTGAGG	CTGTCAGAAA	CTTCCTGGCC	TTCATTTCAGC	1050
ACCTCAGGAC	TGGAAGAAA	GAAGAGATCC	TTCAAATACT	AAAGATGGAA	1100
AATAAGGAAG	TATTACCTCA	GCTGGTGGAT	GCTGTCACCT	CTGCTCAGAC	1150
CTCAGACTCA	TAGAAGCCA	TTTGGACTT	TTTGGATTTC	AAAAGTGACA	1200
GCAGCATCT	CCTCCAGGAG	AGGTTTCTCT	ATGCTGTGG	ATTGCTTCT	1250
CATCCCAATG	AAGAACTOCT	GAGAGCOCTC	ATTAGTAAGT	TCAAAGGTTC	1300
TATTGGTAGC	AGTGACATCA	GAGAACTGT	TATGATCATC	ACTGGGACAC	1350
TTGTCAGAAA	GTTGTGTCAG	AATGAAGGCT	GCAAACTCAA	AGCAGTAGTG	1400
GAAGCTAAGA	AGTTAATCCT	GGGAGGACTT	GAAAAAGCAG	AGAAAAAAGA	1450
GGACACCAGG	ATGTATCTGC	TGGCTTTGAA	GAATGCCCTG	CTTCCAGAAG	1500
GCATCCCAAG	TCTTCTGAAG	TATGCAGAAG	CAGGAGAAGG	GCCCATCAGC	1550
CACCTGGCTA	CCACTGCTCT	CCAGAGATAT	GATCTCCCTT	TCATAACTGA	1600
TGAGGTGAAG	AAGACCTTAA	ACAGAATATA	CCACCAAAC	CGTAAAGTTC	1650
ATGAAAAGAC	TGTGGCACT	GCTGCAGCTG	CTATCATTTT	AAATAACAAT	1700
CCATCCTACA	TGGACGTCAA	GAACATCCTG	CTGTCTATTG	GGGAGCTTCC	1750
CCAAGAAATG	AATAAATACA	TGCTGGOCAT	TGTTCAAGAC	ATCCTACGTT	1800
TTGAAATGCC	TGCAAGCAAA	ATTGTGCGTC	GAGTTCTGAA	GGAAATGGTC	1850
GCTCACAATT	ATGACCGTTT	CTCCAGGAGT	GGATCTTCTT	CTGCCTACAC	1900
TGGCTACATA	GAACGTAGTC	CCCGTTGGC	ATCTACTTAC	AGCCTAGACA	1950
TTCTCTACTC	GGGTTCTGGC	ATTCTAAGCA	GAAGTAACCT	GAACATCTTT	2000

2091102

DC21a

-20-

HUMAN cDNA SEQUENCE
(SEQ. ID. NO. 2, continued):

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
CAGTACATTG	GGAAGGCTGG	TCTTCACGGT	AGCCAGGTGG	TTATTGAAGC	2050
CCAAGGACTG	GAAGCCTTAA	TGCAGCCAC	OCTGACGAG	GGGAGGAGA	2100
ACCTTGACTC	CTATGCTGGT	ATGTCAGCCA	TCCTCTTTGA	TGTTGAGCTC	2150
AGACCTGTCA	CCTTTTTTCAA	CGGATACAGT	GATTTGATGT	CCAAAATGCT	2200
GTCAGCATCT	GGCGACCOCTA	TCAGTGIGGT	GAAAGGACTT	ATTCTGCTAA	2250
TAGATCATTG	TCAGGAACCTT	CAGTTACAAT	CTGGACTAAA	AGCCAATATA	2300
GAGGTCCAGG	GTGGTCTAGC	TATTGATATT	TCAGGTCCAA	TGGAGTTTAG	2350
CTTGTTGGTAT	CGTGAGTCTA	AAACCCGAGT	GAAAATAGG	GTGACTGTGG	2400
TAATAACCAC	TGACATCACA	GTGGACTCCT	CTTTTGIGAA	AGCTGGCCTG	2450
GAAACAGTA	CAGAAACAGA	AGCAGGCTTG	GAGTTTATCT	CCACAGTGCA	2500
GTTTTCTCAG	TACCAATTCT	TAGTTTGAT	GCAGATGGAC	AAGGATGAAG	2550
CTCCATTGAG	GCAATTTGAG	AAAAAGTACG	AAAGGCTGTC	CACAGGCAGA	2600
GGTTATGTCT	CTCAGAAAAG	AAAAGAAAGC	GTATTAGCAG	GATGTGAATT	2650
COGCTCCAT	CAAGAGAACT	CAGAGATGTG	CAAAGTGGTG	TTTGCCCCCTC	2700
AGCOGGATAG	TACTTCCAGC	GGATGGTTTT	GAACTGACC	TGTGATATTT	2750
TACTTGAATT	TGCTTCCCGG	AAAGGGACAC	AATGTGGCAT	GAATAAGTAC	2800
TGCTCTCTG	AGAGCACAGC	GTTTACATAT	TTAOCGTAT	TTAAGATTTT	2850
TGTAAAAAGC	TACAAAAAAC	TGCAGTTTGA	TCAAATTTGG	GTATATGCAG	2900
TATGCTAACC	ACAGCGTCAT	TTTGAATCAT	CATGTGACGC	TTTCAACAAC	2950
GTTCTTAGTT	TACTTATAAC	TCTCTCAAAT	CTCATTTGGT	ACAGTCAGAA	3000

2091102

DC21a

-21-

HUMAN cDNA SEQUENCE
(SEQ. ID. NO. 2, continued)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TAGTTATTCT	CTAAGAGGAA	ACTAGTGTTT	GTAAAAACA	AAAATAAAAA	3050
CAAAACCACA	CAAGGAGAAC	CCAATTTTGT	TTCAACAATT	TTTGATCAAT	3100
GTATATGAAG	CTCTTGATAG	GACTTCCTTA	AGCATGACCG	GAAAACCAAA	3150
CAOGTTCOCT	AATCAGGAAA	AAAAAAAAAA	AAAAA		3185

DC21a

- 22 -

BOVINE/HUMAN cDNA SEQUENCE COMPARISON

[illegible]

DC21a

-23-

BOVINE/HUMAN cDNA SEQUENCE COMPARISON

[illegible]

DC21a

- 24 -

BOVINE/HUMAN cDNA SEQUENCE COMPARISON

[illegible]

2091102

DC21a

-25-

BOVINE PROTEIN SEQUENCE
(SEQ. ID. NO. 3)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
KLTYSTEVEL	DRGKGNLQDS	VGRISSNVD	VALLWRSPDG	CCNQLIQITM	50
FDVNLENVNQ	QRGEKSIFKG	FKSSQIIRKE	NLEAMQRPVL	LHLIHGKIKE	100
FYSYQNEPAA	IENLKRGLAS	LFQMQLSSGT	TNEVDISGDC	KVTYQAHQJK	150
VTKIKALDSC	KIERAGFTTP	HQVLGVTSKA	TSVTTYKIED	SFWAVLSEE	200
IRALRLNFIQ	SIAGKIVSRQ	KLELKTTEAS	VRKPGKQVA	AIKAVDSKY	250
TAIPVGVQVF	QSKCKGCPSL	SEHWQSIRKH	LQPDNLKAE	AVRSFLAFIK	300
ILRTAKKEEI	LQIIKAENKE	VLPQLVDAVT	SAQTPDSLDA	ILDFLDFKST	350
ESVILQERFL	YACAFASHPD	EELLRALISK	FKGSFGNDI	RESVMIIGA	400
LVRKLCQNGG	CKLKGVTIAK	KLILGGLEKA	EKKEDIVMYL	LALKNARLPE	450
GIPLLLKYTE	TGEGPISHLA	ATTLOQYDVP	FTIDEVKKIM	NRIYHQNRKI	500
HEKIVRTTAA	AIILKNPSY	MEVKNILLSI	GELPKENKY	MLSTVQDILR	550
FETPASKMVR	QVLKEMVAHN	YDRFSKSGSS	SAYTG/VERT	SHSASTYSID	600
ILYSGSGILR	RSNLNIFOYT	EKTPLHGIQV	VIEAQGLEAL	LAATPDEGEE	650
NLDSYAGLSA	LLFDVQLRPV	TFENGYSILM	SKMLSASSDP	MSVVKGLLLL	700
IDHSQELQLQ	SGLKAMDVQ	GGLAIDITGA	MEFSILWYRES	KTRVKNRVSV	750
LITGGITVDS	SFVKAGLEIG	AETEAGLEFI	STVQFSQYPF	LVCLQMDKED	800
VPYRQETKY	ERLSTGRGYI	SRKRKESLIG	GCEFP LHQEN	SDMCKVVFAP	850
QPESSSSGWF					860

2091102

DC21a

-26-

HUMAN PROTEIN SEQUENCE
(SEQ. ID. NO. 4)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
MILLAVLFLC	FISSYSASVK	GHTIGLSLNN	DRLYKLTYST	EVLLDRGK GK	50
LQDSVGYRIS	SNVDVALLWR	NPDGDDQLI	QITMKDVNVE	NVNQORGEKS	100
IFKKGKSPSKI	MGKENLEALQ	RPTLLHLING	KVKEFYSYQN	EAVAIENIKR	150
GIASLFOTQL	SSGTINEVDI	SENCKVTYQA	HODKVIKKA	LDCKIARSG	200
FTTPNQVLGV	SSKATSVTTY	KIEDSFVLAV	LAEETHNFGI	NFLQTIKCKI	250
VSKQKLELKT	TEAGFRMSG	KQAAAIKAV	DSKYTAIP IV	QVFEQSHCKG	300
CPSLSELWRS	TRKYLPDNL	SKAEAVRNEL	AFIQHLRTAK	KEEILQILKM	350
ENKEVLPQLV	DAVTSQTED	SLEAILDFLD	FKSDSSIIILQ	EPFL'ACGFA	400
SHIPNEELLRA	LISKFKLSIG	SSDIRETVMI	ITGILVRKLC	QNEGCKLKAV	450
VEAKKLILGG	LEKAEKGEDT	RMVLLALKNA	LLPEGIPSLL	KYAEAGEGPI	500
SHLATTALQR	YDLPFITDEV	KKTINRIYHQ	NRKVHEKTVR	TAAAAIILNN	550
NPSYMDVKNI	LLSIGELPQE	MNKYMLATVQ	DILRLNPAS	KIVRRVLKEM	600
VAHNYDRFSR	SGSGSAYTGY	IERSPRSAST	YSIDILYSGS	GILRRGNLNI	650
FQYIGKAGLH	GSQVVEAOG	LEALIAATPD	EGEENLDSYA	GMSAILEDVQ	700
LRPVITFNGY	SDLMSKMLSA	SGDPISVWKG	LILLIDHSQE	LQLQSGLKAN	750
IEVQGGLAID	ISGAMEFSLW	YRESKTRVKN	RVTWITTDI	TVDSSFVKAG	800
LETSTETEAG	LEFISTVQFS	QYPFLVOMOM	DKCEAPFROE	EKKYERLSTG	850
RGYVSQKRKE	SVLAGCEFP L	HQENSEMCKV	VFAPOPDSTS	TGWF	894

2091102

DC21a

-27-

HUMAN PROTEIN SEQUENCE
(SEQ. ID. NO. 4, continued)

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
MILLAVLFYC	FISSYSASVK	GHTTGLSLNN	DRLYKLTYST	EVLIDRKGK	50
LQDSVGYRIS	SNVDVALLWR	NPDGDDQLI	QITMKOVNVE	NVNQORGEKS	100
IFKGKSPSKI	MGKENLEALQ	RPTLLHLING	KVKEFYSYQN	EAVAIENIKR	150
GLASLFQTQL	SSGTTNEVDI	SGNCKVTYQA	HQDKVIKKA	IDSCKIARSG	200
FTTPNQVLGV	SSKATSVTTY	KIEDSFVIAV	LAEETHNFGI	NFLQTIKGI	250
VSKQKLELKT	TEAGPRIMG	KQMAAIKAV	DSKYTAIPV	GVVFQSHCKG	300
CPSISELWRG	TRKYLOVDNI	SYAEAVRNFL	AFIQHLRTAK	KEFIIQILKM	350
ENKEVLPOLV	DAVISQOTSD	SLEAIDFLD	FKSDSSIILO	FRFLYACGFA	400
SHIPNEELLRA	LISKFKGSIG	SSDIRETVM	ITGTLVRKLC	QNEGCKLKAV	450
VEAKKLILGG	LEKAEKEDT	RMILLALKNA	LLPEGIPSLI	KYAEAGEGPI	500
SHLATTALQR	YDLFITDEV	KKTINRIYHQ	NRKVHEKTVR	TAAAIILNN	550
NPSYDVKNH	LLSIGELPQE	MNKYMLAIQ	DILRFEMPAS	KIVRFVLKEM	600
VAHNYDRFSR	SGSSSAYTGY	IERSPRSAST	YSLDILYSGS	GILRRSNLNI	650
FUYIGKAGLH	GSQVTEACG	LEALIAATPD	EGFENIDSYA	QMSAILEDVQ	700
LRPVTFNGY	SDIMSKMLSA	SGDPISVVK	LILLIDHSQE	LQLQSGLKAN	750
IEVQGLAID	ISGAMEFSLW	YRESKTRVKN	RVTWITTDI	TVDSSEVKG	800
LETSTETEAG	LEFISTVQFS	MPFLVCMQM	DKDEAPFRQF	EFKVERLSTG	850
RGYVSQKRKE	SVLAGCEFP	HQENSEMCKV	VFAPQPDSTS	SGVF	894

2091102

DC21a

-28-

BOVINE/HUMAN PROTEIN COMPARISON

BOVINE	-----	KLTYST EVLDRGKGN	16
HUMAN	MILAVLFLC FISSYSASVK GHTTGLSLNN DRLY	KLTYST EVLDRGKGN	50
BOVINE	LQDSVGYRIS SNVDVALLWR SPDGDL	OLI QITMKDVM E NVNQORGEKS	66
HUMAN	LQDSVGYRIS SNVDVALLWR SPDGDL	OLI QITMKDVM E NVNQORGEKS	100
BOVINE	IFKGGKSSQI IKKENLEA Q RPALLHLING KQGFYSYQN EPAIENR		116
HUMAN	IFKGGKSSQI IKKENLEA Q RPALLHLING KQGFYSYQN EPAIENR		150
BOVINE	GLASLFO QI SSGTTNEVDI SGCKVTYQA HODKVKIKK LDSCKIPAG		166
HUMAN	GLASLFO QI SSGTTNEVDI SGCKVTYQA HODKVKIKK LDSCKIPAG		200
BOVINE	FTTP QVLGV KSKATSVITY KIEDSFVAV DEETRALRL NFLQID GKI		216
HUMAN	FTTP QVLGV KSKATSVITY KIEDSFVAV DEETRALRL NFLQID GKI		250
BOVINE	VSQKLELKT TEAGVRLKSG KQAAIYKAV DSKYTAIPIV GQVFOS CKG		266
HUMAN	VSQKLELKT TEAGVRLKSG KQAAIYKAV DSKYTAIPIV GQVFOS CKG		300
BOVINE	CPSLED S S DRK LQPDNL SKAEAVRFL AFIDHLATK KEEILQILK		316
HUMAN	CPSLED S S DRK LQPDNL SKAEAVRFL AFIDHLATK KEEILQILK		350
BOVINE	ENKEVLPQLV DAVTSAQT D SIAILDFLD FKSTHS ILO ERFLYACFA		366
HUMAN	ENKEVLPQLV DAVTSAQT D SIAILDFLD FKSTHS ILO ERFLYACFA		400
BOVINE	SHNEELLRA LISKFKGSG S SIREVMI IIGLVRLC QNEGCKLRM		416
HUMAN	SHNEELLRA LISKFKGSG S SIREVMI IIGLVRLC QNEGCKLRM		450
BOVINE	TEAFKLIILGG LEKAERKEDI VYLLALKNA ALPEGIPLL KYDEEGEPI		466
HUMAN	TEAFKLIILGG LEKAERKEDI VYLLALKNA ALPEGIPLL KYDEEGEPI		500
BOVINE	SHLNT LQR YD PFITDEV KKT NRIYHQ NKRHEKTVR TAAAILN		516
HUMAN	SHLNT LQR YD PFITDEV KKT NRIYHQ NKRHEKTVR TAAAILN		550
BOVINE	NPSYMEVNI LLSIGELP E MNKYMSIVQ DILRFE PAS KVPVLKEM		566
HUMAN	NPSYMEVNI LLSIGELP E MNKYMSIVQ DILRFE PAS KVPVLKEM		600
BOVINE	VAHNYDRFSK SGSSSAYTCY LRTSISAST YSLDILYSGS GILRRSNLNI		616
HUMAN	VAHNYDRFSK SGSSSAYTCY LRTSISAST YSLDILYSGS GILRRSNLNI		650

2091102

DC21a

-29-

BOVINE/HUMAN PROTEIN COMPARISON

BOVINE	FQYLEKTHLN GQVVVIEAQG LEALIAATPD EGEENLDSYA G SALLFDVQ	666
HUMAN	FQYLEKTHLN GQVVVIEAQG LEALIAATPD EGEENLDSYA G SALLFDVQ	700
BOVINE	LRPVTFNGY SDLMSKMLSA SDP SVVKG LLLIDHSQE LQLQSGLKN	716
HUMAN	LRPVTFNGY SDLMSKMLSA SDP SVVKG LLLIDHSQE LQLQSGLKN	750
BOVINE	MDVQGLAID IEGAMEFSLW YRESKTRVGN RVMLITGDI TVDSSFVKAG	766
HUMAN	MDVQGLAID IEGAMEFSLW YRESKTRVGN RVMLITGDI TVDSSFVKAG	800
BOVINE	IEIGMETEAG LEFISTVQFS QYFFLVQCM DKEDVPRQF EDKYERLSTG	816
HUMAN	LEISTETEAG LEFISTVQFS QYFFLVQCM DKEDVPRQF EDKYERLSTG	850
BOVINE	RGYLSKKE SLICCEFFPL HQENSEMCKV VFAPQPSIS SGWF	860
HUMAN	RGYLSKKE SLVAGCEFFPL HQENSEMCKV VFAPQPSIS SGWF	894

2091102

DC21a

- 30 -

5 The bovine cDNA is a 2900 base composite of the cDNA sequences of clones 2 and 22 and has an open reading frame between bases 1 and 2580, predicting a translation product of 860 amino acids, followed by a TGA stop codon, 298 bases of 3 prime non-coding sequence, and a poly A region.

In the human cDNA, the 3185 bases predict an 894 amino acid translation product from bases 48 to 2729, followed by a TGA stop codon, 435 bases of 3 prime non-coding sequence, and a poly A region.

10 In the cDNA comparison, there is about an 88% identity between overlapping sequences in the coding region (bovine bases 1-2583 and human bases 150 - 2732). It is not necessary to introduce any gaps to attain this alignment within the coding region. The homology is somewhat weaker in the 3' noncoding
15 region, including the introduction of several gaps to obtain optimal alignment.

The bovine protein sequence (SEQ. ID. NO. 3) is the 860 amino acid translation product of the combined sequence of bovine cDNA clones 2 and 22. Sequences for the peptide
20 fragments used to design oligonucleotide probes are as follows: peptide 19A is found between residues 37 and 51, peptide 37A between residues 539 and 550, and peptide 2A between residues 565 and 572.

25 The human protein sequence (SEQ. ID. NO. 4) is the 894 amino acid translation product of human cDNA clone 693.

In the amino acid comparison, the bovine protein shows about 86% identity to the human translation product. When considering highly conserved substitutions at nonidentical residues, the two proteins are about 94 % homologous.

30 The inventors extended their knowledge of the 5' end of the foregoing bovine cDNA sequence with the sequence shown below, 5' to 3'. The top line shows the nucleotide sequence (SEQ. ID. NO. 5), and the bottom line the amino acid sequence (SEQ. ID. NO. 6). The new sequence obtained (83 bases) is underlined.

2091102

DC21a

- 31 -

TT TTT CTC TGC TTC ATT TCC TCA TAT TCA GCT TCT
 F L C F I S S Y S A S
 GTT AAA GGT CAC ACA ACT GGT CTC TCA TTA AAT AAT
 V K G H T T G L S L N N
 5 GAC CGA CTA TAC AAA CTC ACA TAC TCC ACT GAA GTT
 D R L Y K L T Y S T E V

The Inventors have also extended their knowledge of the 5' end of the foregoing human cDNA sequence. The additional sequence (SEQ. ID. NO. 7) is as follows:

10 AGAGTCCACTTCTCA

This sequence extends the 5' end of the human MTP cDNA sequence by 15 bases. These sequences were generated from human liver cDNA clone 754 isolated during the initial human cDNA cloning (see Example 3), but were characterized after clone 15 693.

The Inventors have also elucidated a partial human genomic DNA sequence (SEQ. ID. NO. 8) for the high molecular weight subunit of MTP as shown below. Vertical lines indicate intron/exon boundaries. Exon sequences are in plain type, intron sequences in bold. Arrows indicate portions of the introns for which the sequence is not reported (arrow lengths do not indicate the size of the introns). The numbers in the right column indicate the first and last base of each exon relative to the human cDNA sequence shown *supra*. This extended genomic nucleic acid, as 20 well as the extended cDNA, and fragments thereof are useful in 25 the present invention.

2091102

-32-

DC21a

(SEQ. ID. NO. 8)

AAGGTTCTGAGCCCCACTGTGGTAGAGAGATGCACTGATGGTGAGACAG
CATGTTCCCTTACAATGAAAAGTGGATATGTGTCATTATCTTTATGCAGG 109
TCACACAAGTGGTCTCTCATTAAATAATGACCGGCTGTACAAGCTCACGT
ACTCCACTGAAGTTCTTCTTGATCGGGGCAAAGGAAAAGTGAAGACAGC EXON 2
JTGGSCTACCGCATTTCCTCCAAGTGGATGTGGCCTTACTATGGAGGAA
TCCTGATGGTGTATGATGACCAGTTGATCCAAATAACG|GTGGGCATTTTCT 296
ACCAGATAAATGCAAAGATTAGATATCAGAACTTTTGGAGAAGTGTACC
ATTGGACAGCACTTGTATTGGGTTCCCGTTTATAATCCATTAGTTTCTTA
TCTATCACTAAAACAAGCAGGTCTTTGTTTTAAGGTTTGGTGTATGAAAG →
TTATT.TAAGCCTAAAGTCACAGAGTTCTTTAAGTATTGCTATTTTGGC
TTATTAAAAACCTAGTTTATAAATACCTTCTCCATTCTTTTAAAGTGAG
TGCCAAGGTCCTATAAATCATGAATTGAAAATGACAGAAGAAATGTGG
CCAACCTCTTTCTGTTTCTTTATCATTTTTATTTTCAGAGATACTCTGATGA
AGACAGATATAGGAAGTTTTTTTTAACAGCTTTCTTTCTGTTACTCCAG 297
TGAAGGATGTAAATGTTGAATAATGTGAATCAGCAGAGAGGAGAGAAGAGC
ATCTTCAAAGGAAAAAGCCATCTAAAATAATGGGAAAGGAAAAGTTGGA EXON 3
AGCTCTGCAAAGACCTACGCTCCTTCATCTAATCCATGGAAAG|GTAAAGG 410
GGCGTTTAGATTCCACAAGTTTCTTCTCCAAGTTTCAATTTTTCTTCCCTT
CAGTAGATATTATTTTGAGGTAATCACATTGTAAGTACTTTTATGGTAA
TGGAATTTCTTCAAGAACTAAAGAACAGAGGTTGTAAATTAAATGTTTCC
AACTGAATCAATGCCCTGAGTTCCCTTACATTACTAGCCAATTGTTT
CCTATTTTCTGGAAATCTTTATAGTGGAAATGAAGTATTTATTTATTGAT
GAAAGGCATTATTAAAGGTAAATTTCTCATCAATTATAAGGGATTACA
AACATAATGTAACAAGCAAGTCATCAAGCATGATTGGATGAATTC →

2091102

-33-

DC21a

(SEQ. ID. NO. 8, continued)

TCTGATAAATGATGCATTTTGGCTTCATTTGTGTTCTGTTCCCTCTCCC
 CACCAGGTCAAAGAGTTCTACTCATATCAAAATGAGGCAGTGGCCATAGA 441
 AATATCAAGAGAGGTCTGGCTAGCCTATTTTCAGACACAGTTAAGCTCTG EXON 4
 GAACCACCAATGAGGTACTTACCAATATTAATAAGGATTCAGCATCTCAA 548
 TAAAATTTGTAAGGATTTCTACTTATACAATTTTCAGTAGAAGAGTTACTA
 CTAAGGTAATGCTCAGAAAAGGTGACTTGTGTAG →
 TCCCCTATGGCCTATTAGAGACCTCAATTTTCAAGCCACTTCTCACTAGA
 ATTCAAATGGCCCACAAGGAATCCCAAGCATTATGCCCTTGCCTTTCTTT
 TTAGGTAGATATCTCTGGAAATGTAAAGTGACCTACCAGGCTCATCAAG 549
 ACAAGTGATCAAAATTAAGGCCTTGGATTTCATGCAAAATAGCGAGGTCT EXON 5
 GGATTTACGACCCCAAATCAGGTATGATAGATGTCACCTTCTTTGAGGCCA 655
 TTAAATAATTACATTTTGTAGAGACTAATTTA →
 CGATGATTACTTGTATATAAGATGGCTATTTATTTATTTAGTCTTGGGT 666
 GTCAGTTCAAAGCTACATCTCTCACCACCTATAAGATAGAAGACAGCTT EXON 6
 TGTATAGCTGTGCTTGTGAAGAAACACACAATTTTGGACTGAATTTCC
 TACAAACCATTAAAGGGGAAAATAGTATCGAAGTAAGATAATGCTAAAATT 805
 TTTATTTTCTTTGCTATTCTTTGTTATATTATTATACTTGATTGT →
 ATGATTATAATATAGCATTTCCTTTGGTATTATGCAGTSCAGAAATTAGA 806
 GCTGAAGACAACCGAAGCAGGCCCAAGATTGATGTCTGGAAAGCAGGCTG EXON 7
 CAGCCATAATCAAAGCAGTTGATTCAAAGTACACGGCCATTCCCATTGTG
 GGCAGGTCTTCCAGAGCCACTGTAAAGGATGTCCTTCTGTAAGTGCAGA 956
 CAAATATGGGAATAATCATGACATCAGACTCTGTTTTCAATTTGTCTCCA
 GTGAAAGCATCAACTCATTCA →

2091102

-34-

DC21a

(SEQ. ID. NO. 8, continued)

GGAGAACACCCTTTGTAAATGTGGATGTTACAGTTATGAGTGGGGTATG
AGCCTGCAGTGTATGTTTTGCAGCTCTCGGAGCTCTGGCGGTCCACCAGG 957
AAATACCTGCAGCCTGACAACCTTTCCAAGGCTGAGGCTGTCAGAACTT EXON 8
CCTGGCCTTCATTGAGCACCTCAGGACTGCGAAGAAAGAAGAGATCCTTC
AAATACTAAAGATGGAAAATAAGGAAGTATTGTAAGTTCCCCAACCTTTG 1114
TGTGGGGTTGCTCTGTCAGAAACATTCTGGAGTG →
GATATCCATGATTATGCCTTTTTTTATAGACCTCAGCTGGTGGATGCTGT 1115
CACCTCTGCTCAGACCTCAGACTCATTAGAAGCCATTTTGGACTTTTGG EXON 9
ATTTCAAAGTGACAGCAGCATTATCCTCCAGGAGAGGTTTCTCTATGCC
TGTGGATTGCTTCTCATCCCAATGAAGAACTCCTGAGAGCCCTCATTGT 1283
AAGTCAAATAGAAAATAAGACCCTCAACTCCTATAAACTTCTTAAGAA
TATTAACAGTAATTAAAAGTTTCTTAGATCCGAATTCTTCGCCCTATAGT
GAGTCA →
CTATTTTATCCCTGGGTGGTTAATAGAGTAAGTTCAAAGGTTCTATTGGT 1284
AGCAGTGACATCAGAGAACTGTTATGATCATCACTGGGACACTTGTGAG EXON 10
AAAGTTGTGTCAGAAATGAAGGCTGCAAACTCAAAGTAAGTGCAAATCCAA 1391
TCTCATGTATTACATCATTCTACACCATGTGCCATTTGATACTCACCATG
CTGCCTACTATTGGCACTCCTAATTCTCTTTACTCTATTCTACTTACCTT
ATTGATAGCAAT →

2091102

-35-

DC21a

(SEQ. ID. NO. 8, continued)

AACACAATATGCCCATTTATTGATAATACTCATTGCTTCTTAAGAATGTAT
ATGTATTTTTTTTTAAAAAAGCATAACACCTTTATCARSCTTTACTTGTT
TGCTTTTATTCCACTGTGTGCCTCAGTCAAGCAACCAATGCAAAACCTTG
TAAACTGTAGGTTGCTTTCTTGGACCCAAGAATAAAGCCAGTCTCACCC
AAGTCTTCTTCAATGTATGGTCATGCATATATCTAAGGTATATGATTTTT
CAGGCAGTAGTGGAAGCTAAGAAGTTAATCCTGGGAGGACTTGAAAAAGC 1392
AGAGAAAAAAGAGGACACCAGGATGTATCTGCTGGCTTTGAAGAATGCCC
TGCTTCCAGAAGGCATCCCAAGTCTTCTGAAGTATGCTGAAGCAGGAGAA EXON 11
GGGCCCCATCAGCCACCTGGCTACCACTGCTCTCCAGAGATATGATCTCCC
TTTCATAACTGATGAGGTAAAATCTCCAAGAATATTTGCCAACATTTACAG 1504
AAGAAAAAAGCATGCTGAACATGAGTCAATGCCAATTCCGCTCA
AGTCACTCTGTATTTTCCCCAATAGTCTTCTCTCTGCTTAAAAATAAC
TCTTAAATTGCATTTGGGGCTATTCTAA —————→
ATGTTTAATTTCTCAGGCTATGCCTAATGTGCATAAGGAAGTATGTGGTC
TGAAGTTCACTACAGTCATGGAAGAAAGAGATGGAGAAAGCCACCAGCTC
TTAACGGCCTCAGCCTAGAAGTGATCCTCATAGATTCTATCCATGGCGTA
TTAGCCAGAACTAGTCACGTGGCCCCCACCAAATCACAANGGAATCTGGG
AAATGTAGTAACACATGTATATTTTTATGAACACTCACTATTCTGCTAT
TCCTGCTGAAATGTCCATTTTAAAAATCTAGATGTGCACTAAGTTTGAAC
ATCTTATGAACAGGTGAAGAAGACCTTAAACAGAATATACCACCAAAACC 1605
GTAAAGTTCATGAAAAGACTGTCCGCACTGCTGCAGCTGCTATCATTTTA
AATAACAATCCATCCTACATGGACGTCAAGAACATCCTGCTGTCTATTGG EXON 12
GGAGCTTCCCCAAGAAATGAATAAATACATGCTCGCCATTGTTCAAGACA
TCCTACGTTTTGAAATGCCTGCAAGGTATAATACATTGCACATGTCTCTC 1816
TGTGTATTCAAGCTTATTTGTGTGTTCATGGGGTACCGATGTAGCTAATA
ATAATGATGTGGTCATTATGCAA —————→

2091102

-36-

DC21a

(SEQ. ID. NO. 8, continued)

AGCTGGACACCCTTGCCTTGCTGTCATTTTGATAGCAAATAAATTTCAA
ATATCTGAGTAATGAAGGGGCTAGCCCTAATCCTGATGCTACCACGCCAG
CTGGCACCACCCTGGCTCTTGGAAGGCATGAGGAAAATTGGCTTCCTC
TTTTTCCACTGAGGATTTTTTTTCCAAATTGACTTGGGAAACAGTC
ATTACAATGAATGTGCAGCTTTTTTTTCTCATATGTTGCAGCAAAATT 1917
GTCCGTCGAGTTCTGAAGGAAATGGTCGCTCACAATTATGACCGTTTCTC EXON 13
CAGGAGTGGATCTTCTTCTGCCTACACTGGCTACATAGAACSTATGTACA 1914
CCAAAAGAGGTTCTCCTTCCATACCCCACTTACCATTCCTGGAAC
GCTATTAAATTACAGTTATTGTGTGTCATCAGTAGTCCCCGTTCCGGCAT 1915
CTACTTACAGCCTAGACATTCTCTACTCGGGTTCTGGCATTCTAAGGAGA
AGTAACCTGAACATCTTTCAGTACATTGGGAAGGCTGGTCTTCACGGTAG EXON 14
CCAGTAACTCACTTCTCATGGATTTTGCTTAATAAAGTATGCAAGAAAT 2036
CAGGCTGAGGTAAATAAACATATATGCTGTGGGTAATGCTATAGAATG
TATAAGTTAATGGTGGCTTCTGTCAATTTTGGCCATGATTTCTTATCT
GTAAGAGGCTGTATGGTTTATAGTCACTCAGAGAAAGTTTCGAATTTGAA
CTTGAAACCTAAGTAATTTGATCCATTGAACTTGACAAATGTCCATT →
TGGCCCCCTTGAGAAGTTCTAGCTGCAGCTCAGAAGCTTCACCATATTTA
CAGACAGGCAGGGAGCTTCCGTCAATGAACATTATATTGATTTTATCCAG
GTGTTATTGAAGCCCAAGGACTGGAAGCCTTAATCGCAGCCACCCCTGA 2037
CGAGGGGGAGGAGAACCCTTGACTCCTATGCTGGTATGTCAGCCATCCTCT
TTGATGTTTCAGCTCAGACCTGTCACCTTTTCAACGGATACAGTGATTTG EXON 15
ATGTCCAAAATGCTGTCAAGCATCTGGCGACCCTATCAGTGTGGTGAAAGG
ACTTATTCTGCTAATAGATCATTCTCAGTAAATTCANYCAGTCTGTGAGT 2264
ATTATTGAGTCCCTAACTACGCCAGGCACGTA →

2091102

-37-

DC21a

(SEQ. ID. NO. 8, continued)

ATCAACACAACCTCAAATGGAATTATCTACAGCAGGAGGTCAAATGTNCCA
TTGGAAAGGGGGTTAACTAAATTGTACTTATTATTTTATACTATTATT
ATGCTTTTTTCTTCTAGGAACCTTCAGTTACAATCTGGACTAAAAGCCAAT 2265
ATAGAGGTCCAGGGTGGTCTAGCTATTGATATTTTCAGGTGCAATGGAGTT EXON 16
TAGCTTGTGGTATCGTGAGTCTAAAACCCGAGTGAAAAATAGTTAAGTGT 2399
TTATGCATTATACATTTATGAATTACATATAAGACTATAT →
CTTGGGTATTTCTGACCTGCTGAGAGGACCTGGGTTCGAAGAATGTTTTT
CATTTTGGTCTTTGTTATGCCCATACGAAACAATGTAGTATCTTACAGAC
ACTCCCCACATCTGCAACTGAAGCCAGGGGAGAGCTCAGGGGAAGGGCAA
ACCTTCCCTGCCCAATATCTGAGACTCACCAGGCCCTGGTTACCAGCAGA
ACTCTAAGCACATCCAGGTCACCTCTGAATCCCTTAAGTGTTCCTTCCA
GTCACTGGCATCATACGTTCASACCTGTAAAGTTACAGCTGTTAGTCCA
ATACCATTAAATATAATATGAACAAGTTTTTCTTTTTTTCTCAAATGTT
TAGGGTGACTGTGGTAATAACCACTGACATCACAGTGGACTCCTCTTTTG 2390
TGAAAGCTGGCCTGGAAACCACTACAGAAACAGAAGCAGGTTTGGAGTTT
ATCTCCACAGTGCAGTTTTCTCAGTACCCATTCTTAGTTTGCAATGCAGAT EXON 17
GGACAAGGATGAAGCTCCATTTCAGTTAAGATGCAGCGTACAGGTCATGTT 2560
CCAGGACCATCCCCAGTGCACCAGGAACCTTGCATTTCAGTTTAGAACATTC
AGTTTCAGAAATTAACAACAAACAGTAGAAACCCAGGGAAAGATGAATTTT
CTTTAAATGAGTAGAAGAATAATTGATAAGGCCAAAAAAGTCAGTTTCT
GGGATACCAAAAAAATCTAATGACTAGTTTCATGTGATTCTGGAGATAG
TTATCATATTCTAATCCAGAAACATTT →

2091102

-38-

DC21a

(SEQ. ID. NO. 8, continued)

TGCTTTGGAACAGAACTTCAAGTACATTCAGTAACTTGGCTGGAGAGGT
ATAGGGTGACTTAACTGTGTGTGTAAATCTGTTAATGTTGCTGTTGTGT
ACAGGCAATTTGAGAAAAAGTACGAAACGCTGTCCACAGGCAGAGGTTAT 2561
GTCTCTCAGAAAAGAAAAGAAAGCGTATTAGCAGGATGTGAATTCCCGCT
CCATCAAGAGAACTCAGAGATGTGCAAAGTGGTGTGTTGCCCTCAGCCGG
ATAGTACTTCCAGCGGATGGTTTTGAAACTGACCTGTGATATTTACTTG
AATTTGTCTCCCCGAAAGGGACACAATGTGGCATGACTAAGTACTTGCTC
TCTGAGAGCACAGCGTTTACATATTTACCTGTATTTAAGATTTTTGTAAA EXON 18
AAGCTACAAAAAAGTGCAGTTTGATCAAATTTGGGTATATGCAGTATGCT
ACCCACAGCGTCATTTTGAATCATCATGTGACGCTTCAACAACGTTCTT
AGTTTACTTATACCTCTCTCAAATCTCATTGGTACAGTCAGAAATAGTTA
TTCTCTAAGAGGAACTAGTGTGTTGTTAAAAACAAAATAAAAACAAAAC
CACACAAGGAGAACCCAATTTTGTTCACAATTTTGATCAATGTATAT
GAAGCTCTTGATAGGACTTCCTTAAGCATGACGGGAAAACCAAACACGTT
CCCTAATCAGGAAAAAAAAAAAAAAAAAAGGTAGGACACAACCAACCCAT
TTTTTTTCTCTTTTTTTTGAGTTGGGGGCCAGGGAGAAGGGACAAGACT
TTTAAAGACTTGTTAGCCAACCTTCAAGAATTAATATTTATGTCTCTGTT
ATTGTTAGTTTTAAGCCTTAAGGTAGAAGGCACATAGAAATAACATCTCA
TCTTTCTGCTGACCATTTTAGTGAGGTTGTTCCAAAGACATTCAGGTCTC
TACCTCCAGCCCTGCAAAAATATTGGACCTAGCACAGAGGAATCAGGAAA
ATTAATTCAGAACTCCATTTGATTTTTCTTTTGCTGTGTCTTTTTGAG
ACTGTAATATGGTACACTGTCCTCTAAGGGACATCCTCATTTTATCTCAC

2091102

-39-

DC21a

(SEQ. ID. NO. 8, continued)

CTTTTGGGGGTGAGAGCTCTAGTTCATTTAACTGTACTCTGCACAATAG
CTAGGATGACTAAGAGAACATTGCTTCAAGAACTGGTGGATTGGATT
CCAAAATATGAAATAAGGAAAAAATGTTTTATTGTATGAATTAAAG
ATCCATGTTGAACATTTGCAAATATTTATTAATAAACAGATGTGGTGATA
AACCCAAAACAAATCACAGGTCCTTATTTTCCACTAAACACAGACACATG
AAATGAAAGTTTAGCTAGCCCACTATTTGTTGTAAATTGAAAACGAAGTG
TGATAAAATAAATATGTAGAAATCATATTGAATTC

5 The nucleic acids of the present invention can be isolated from a variety of sources, although the presently preferred sequences have been isolated from human and bovine cDNA and human genomic libraries. The exact amino acid sequence of the polypeptide molecule produced will vary with the initial DNA sequence.

The nucleic acids of the present invention can be obtained using various methods well-known to those of ordinary skill in the art. At least three alternative principal methods may be employed:

- 10 (1) the isolation of a double-stranded DNA sequence from genomic DNA or complementary DNA (cDNA) which contains the sequence;
- (2) the chemical synthesis of the DNA sequence; and
- 15 (3) the synthesis of the DNA sequence by polymerase chain reaction (PCR).

In the first method, a genomic or cDNA library can be screened in order to identify a DNA sequence coding for all or part of the high molecular weight subunit of MTP. For example, bovine or human cDNA libraries can be screened in order to identify a

20 DNA sequence coding for all or part of MTP. Various cDNA libraries, for example, a bovine small intestine lambda gt10 library (Clontech Laboratories, Inc. Palo Alto, CA), a human liver lambda UNI-ZAP™ XR library (Stratagene Cloning Systems, La Jolla, CA), or a human intestine lambda gt10 library (Clontech), can be used.

25 Various techniques can be used to screen genomic DNA or cDNA libraries for target sequences that code for the high molecular weight subunit of MTP. This technique may, for example, employ a labeled single-stranded DNA probe with a sequence complementary to a sequence that codes for the high

30 molecular weight subunit of MTP. For example, DNA/DNA hybridization procedures may be used to identify the sequence in the cloned copies of genomic DNA or cDNA which have been denatured to a single-stranded form. Suitable probes include cDNA for the high molecular weight subunit of MTP acquired from

the same or a related species, synthetic oligonucleotides, and the like.

A genomic DNA or cDNA library can also be screened for a genomic DNA or cDNA coding for all or part of the high molecular weight subunit of MTP using immunoblotting techniques.

In one typical screening method suitable for the hybridization techniques, a genomic DNA or cDNA library is first spread out on agarose plates, and then the clones are transferred to filter membranes, for example, nitrocellulose membranes. The genomic library is usually contained in a vector such as EMBL 3 or EMBL 4 or derivatives thereof (e.g., lambda DASH™). The cDNA library is usually contained in a vector such as λ gt10, λ gt11, or lambda ZAP. A DNA probe can then be hybridized to the clones to identify those clones containing the genomic DNA or cDNA coding for all or part of the high molecular weight subunit of MTP.

Alternatively, appropriate *E. coli* strains containing vectors λ gt11 or lambda ZAP can be induced to synthesize fusion proteins containing fragments of proteins corresponding to the cDNA insert in the vector. The fusion proteins may be transferred to filter membranes, for example, nitrocellulose. An antibody may then be bound to the fusion protein to identify all or part of the high molecular weight subunit of MTP.

In the second method, the nucleic acids of the present invention coding for all or part of MTP can be chemically synthesized. Shorter oligonucleotides, such as 15 to 50 nucleotides, may be directly synthesized. For longer oligonucleotides, the DNA sequence coding for the high molecular weight subunit of MTP can be synthesized as a series of 50-100 base oligonucleotides that can then be sequentially ligated (via appropriate terminal restriction sites) so as to form the correct linear sequence of nucleotides.

In the third method, the nucleic acids of the present invention coding for all or part of the high molecular weight subunit of MTP can be synthesized using PCR. Briefly, pairs of synthetic

DNA oligonucleotides generally at least 15 bases in length (PCR primers) that hybridize to opposite strands of the target DNA sequence are used to enzymatically amplify the intervening region of DNA on the target sequence. Repeated cycles of heat
5 denaturation of the template, annealing of the primers and extension of the 3'-termini of the annealed primers with a DNA polymerase results in amplification of the segment defined by the PCR primers. See White, T.J. et al., Trends Genet. 5, 185-9 (1989).

10 The nucleic acids of the present invention coding for all or part of MTP can also be modified (i.e., mutated) to prepare various mutations. Such mutations may change the amino acid sequence encoded by the mutated codon, or they may be silent and not change the amino acid sequence. These modified nucleic acids
15 may be prepared, for example, by mutating the nucleic acid coding for the high molecular weight subunit of MTP so that the mutation results in the deletion, substitution, insertion, inversion or addition of one or more amino acids in the encoded polypeptide using various methods known in the art. For example, the methods of
20 site-directed mutagenesis described in Taylor, J. W. et al., Nucl. Acids Res. 13, 8749-64 (1985) and Kunkel, J. A., Proc. Natl. Acad. Sci. USA 82, 482-92 (1985) may be employed. In addition, kits for site-directed mutagenesis may be purchased from commercial vendors. For example, a kit for performing site-directed
25 mutagenesis may be purchased from Amersham Corp. (Arlington Heights, IL). In addition, disruption, deletion and truncation methods as described in Sayers, J. R. et al., Nucl. Acids Res. 16, 791-800 (1988) may also be employed. Mutations may be advantageous in producing or using the polypeptides of the
30 present invention. For example, these mutations may modify the function of the protein (e.g., result in higher or lower activity), permit higher levels of protein production or easier purification of the protein, or provide additional restriction endonuclease recognition sites in the nucleic acid. All such modified nucleic

acids and polypeptide molecules are included within the scope of the present invention.

Expression vectors

5 The present invention further concerns expression vectors comprising a DNA sequence coding for all or part of the high molecular weight subunit of MTP or a protein complex comprising both the high and low molecular weight subunits or portions thereof. The expression vectors preferably contain all or part of
10 the DNA sequence having the nucleotide sequence shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8. Further preferred are expression vectors comprising one or more regulatory DNA sequences operatively
15 linked to the DNA sequence coding for all or part of the high molecular weight subunit of MTP. As used in this context, the term "operatively linked" means that the regulatory DNA sequences are capable of directing the replication and/or the expression of the DNA sequence coding for all or part of the high molecular weight
20 subunit of MTP.

 Expression vectors of utility in the present invention are often in the form of "plasmids", which refer to circular double stranded DNA loops that, in their vector form, are not bound to the chromosome. However, the invention is intended to include such
25 other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto. The expression vectors of the present invention may also be used to stably integrate the DNA sequence encoding the high molecular weight subunit of MTP into the chromosome of an appropriate host
30 cell (e.g., COS or HepG2 cells).

 Expression vectors useful in the present invention typically contain an origin of replication, a promoter located 5' to (i.e., upstream of) the DNA sequence, followed by the DNA sequence coding for all or part of the high molecular weight subunit of MTP,

transcription termination sequences, and the remaining vector. The expression vectors may also include other DNA sequences known in the art, for example, stability leader sequences which provide for stability of the expression product, secretory leader
5 sequences which provide for secretion of the expression product, sequences which allow expression of the structural gene to be modulated (e.g., by the presence or absence of nutrients or other inducers in the growth medium), marking sequences which are capable of providing phenotypic selection in transformed host
10 cells, sequences which provide sites for cleavage by restriction endonucleases, and sequences which allow expression in various types of hosts, including but not limited to prokaryotes, yeasts, fungi, plants and higher eukaryotes. The characteristics of the actual expression vector used must be compatible with the host
15 cell which is to be employed. For example, when expressing DNA sequences in a mammalian cell system, the expression vector should contain promoters isolated from the genome of mammalian cells, (e.g., mouse metallothionein promoter), or from viruses that grow in these cells (e.g., vaccinia virus 7.5 K promoter). An
20 expression vector as contemplated by the present invention is at least capable of directing the replication, and preferably the expression, of the nucleic acids of the present invention. Suitable origins of replication include, for example, the Col E1, the SV40 viral and the M13 origins of replication. Suitable promoters
25 include, for example, the cytomegalovirus promoter, the lac Z promoter, the gal 10 promoter and the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) polyhedral promoter. Suitable termination sequences include, for example, the bovine growth hormone, SV40, lac Z and AcMNPV polyhedral
30 polyadenylation signals. Examples of selectable markers include neomycin, ampicillin, and hygromycin resistance and the like. All of these materials are known in the art and are commercially available.

Suitable commercially available expression vectors into which the DNA sequences of the present invention may be inserted include the mammalian expression vectors pcDNA1 or pcDNA/Neo, the baculovirus expression vector pBlueBac, the
5 prokaryotic expression vector pcDNA11 and the yeast expression vector pYes2, all of which may be obtained from Invitrogen Corp., San Diego, CA.

Suitable expression vectors containing the desired coding and control sequences may be constructed using standard
10 recombinant DNA techniques known in the art, many of which are described in Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989).

15 Host cells

The present invention additionally concerns host cells containing an expression vector which comprises a DNA sequence coding for all or part of the high molecular weight subunit of MTP. See, for example the host cells of Example 4
20 hereinbelow, which are preferred. The host cells preferably contain an expression vector which comprises all or part of the DNA sequence having the nucleotide sequence substantially as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, and the first 108
25 bases of 2 together with 7 and 8. See, for example, the expression vector appearing in Example 4 hereinbelow, which is preferred. Further preferred are host cells containing an expression vector comprising one or more regulatory DNA sequences capable of directing the replication and/or the
30 expression of and operatively linked to a DNA sequence coding for all or part of the high molecular weight subunit of MTP. Suitable host cells include both prokaryotic and eukaryotic cells. Suitable prokaryotic host cells include, for example, E. coli strains HB101, DH5a, XL1 Blue, Y1090 and JM101. Suitable eukaryotic

host cells include, for example, Spodoptera frugiperda insect cells, COS-7 cells, human skin fibroblasts, and Saccharomyces cerevisiae cells.

5 Expression vectors may be introduced into host cells by various methods known in the art. For example, transfection of host cells with expression vectors can be carried out by the calcium phosphate precipitation method. However, other methods for introducing expression vectors into host cells, for example, electroporation, liposomal fusion, nuclear injection, and viral or
10 phage infection can also be employed.

Once an expression vector has been introduced into an appropriate host cell, the host cell may be cultured under conditions permitting expression of large amounts of the desired polypeptide, in this case a polypeptide molecule comprising all or
15 part of the high molecular weight subunit of MTP.

Host cells containing an expression vector that contains a DNA sequence coding for all or part of the high molecular weight subunit of MTP may be identified by one or more of the following six general approaches: (a) DNA-DNA hybridization; (b) the
20 presence or absence of marker gene functions; (c) assessing the level of transcription as measured by the production of mRNA transcripts encoding the high molecular weight subunit of MTP in the host cell; (d) detection of the gene product immunologically; (e) enzyme assay; and (f) PCR.

25 In the first approach, the presence of a DNA sequence coding for all or part of the high molecular weight subunit of MTP can be detected by DNA-DNA or RNA-DNA hybridization using probes complementary to the DNA sequence.

30 In the second approach, the recombinant expression vector host system can be identified and selected based upon the presence or absence of certain marker gene functions (e.g., thymidine kinase activity, resistance to antibiotics, etc.). A marker gene can be placed in the same plasmid as the DNA sequence coding for all or part of the high molecular weight subunit of MTP

under the regulation of the same or a different promoter used to regulate the MTP coding sequence. Expression of the marker gene indicates expression of the DNA sequence coding for all or part of the high molecular weight subunit of MTP.

5 In the third approach, the production of mRNA transcripts encoding the high molecular weight subunit of MTP can be assessed by hybridization assays. For example, polyadenylated RNA can be isolated and analyzed by Northern blotting or a
10 nuclease protection assay using a probe complementary to the RNA sequence. Alternatively, the total RNA of the host cell may be extracted and assayed for hybridization to such probes.

15 In the fourth approach, the expression of all or part of the high molecular weight subunit of MTP can be assessed immunologically, for example, by immunoblotting with antibody to MTP (Western blotting).

20 In the fifth approach, expression of the high molecular weight subunit of MTP can be measured by assaying for MTP enzyme activity using known methods. For example, the assay described herein below may be employed.

25 In the sixth approach, oligonucleotide primers homologous to sequences present in the expression system (i.e., expression vector sequences or MTP sequences) are used in a PCR to produce a DNA fragment of predicted length, indicating incorporation of the expression system in the host cell.

30 The DNA sequences of expression vectors, plasmids or DNA molecules of the present invention may be determined by various methods known in the art. For example, the dideoxy chain termination method as described in Sanger et al., Proc. Natl. Acad. Sci. USA 74, 5463-7 (1977), or the Maxam-Gilbert method as described in Proc. Natl. Acad. Sci. USA 74, 560-4 (1977) may be employed.

 In order to express catalytically active MTP, it may be necessary to produce a protein complex containing both the high and low molecular weight subunits of MTP. The low molecular

weight subunit of MTP is the previously characterized protein, protein disulfide isomerase (PDI). PDI cDNAs have been cloned from human [Pihlajaniemi *et al.*, EMBO J. 6, 643-9 (1987)], bovine [Yamaguchi *et al.*, Biochem. Biophys. Res. Comm. 146, 1485-92 (1987)], rat [Edman *et al.*, Nature 317, 267-70 (1985)] and chicken [Kao *et al.*, Connective Tissue Research 18, 157-74 (1988)].

Various approaches can be used in producing a protein containing both the high and low molecular weight subunits of MTP. For example, cDNA sequences encoding the subunits may be inserted into the same expression vector or different expression vectors and expressed in an appropriate host cell to produce the protein.

It should, of course, be understood that not all expression vectors and DNA regulatory sequences will function equally well to express the DNA sequences of the present invention. Neither will all host cells function equally well with the same expression system. However, one of ordinary skill in the art may make a selection among expression vectors, DNA regulatory sequences, and host cells using the guidance provided herein without undue experimentation and without departing from the scope of the present invention.

Polypeptides

The present invention further concerns polypeptide molecules comprising all or part of the high molecular weight subunit of MTP, said polypeptide molecules preferably having all or part of the amino acid sequence as shown in SEQ. ID. NOS. 3, 4, or 3 together with 6. In the case of polypeptide molecules comprising part of the high molecular weight subunit of MTP, it is preferred that polypeptide molecules be at least about 5 to 8 sequential amino acids in length, more preferably at least about 15 to 20 sequential amino acids in length. Also preferred are polypeptides at least about 180 sequential amino acids in length.

which may approximate the size of a structural domain within the protein.

All amino acid sequences are represented herein by formulas whose left-to-right orientation is in the conventional
5 direction of amino-terminus to carboxy-terminus.

The polypeptides of the present invention may be obtained by synthetic means, i.e., chemical synthesis of the polypeptide from its component amino acids, by methods known to those of ordinary skill in the art. For example, the solid phase procedure
10 described by Houghton et al., Proc. Natl. Acad. Sci. 82, 5131-5 (1985) may be employed. It is preferred that the polypeptides be obtained by production in prokaryotic or eukaryotic host cells expressing a DNA sequence coding for all or part of the high molecular weight subunit of MTP, or by in vitro translation of the
15 mRNA encoded by a DNA sequence coding for all or part of the high molecular weight subunit of MTP. For example, the DNA sequence of SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8 or any part thereof may be
20 synthesized using PCR as described above and inserted into a suitable expression vector, which in turn may be used to transform a suitable host cell. The recombinant host cell may then be cultured to produce the high molecular weight subunit of MTP. Techniques for the production of polypeptides by these means are
25 known in the art, and are described herein.

The polypeptides produced in this manner may then be isolated and purified to some degree using various protein purification techniques. For example, chromatographic procedures such as ion exchange chromatography, gel filtration
30 chromatography and immunoaffinity chromatography may be employed.

The polypeptides of the present invention may be used in a wide variety of ways. For example, the polypeptides may be used to prepare in a known manner polyclonal or monoclonal

antibodies capable of binding the polypeptides. These antibodies may in turn be used for the detection of the polypeptides of the present invention in a sample, for example, a cell sample, using immunoassay techniques, for example, radioimmunoassay, enzyme immunoassay, or immunocytochemistry. The antibodies may also be used in affinity chromatography for isolating or purifying the polypeptides of the present invention from various sources.

5 The polypeptides of the present invention have been defined by means of determined DNA and deduced amino acid sequencing. Due to the degeneracy of the genetic code, other DNA sequences which encode the same amino acid sequences depicted in SEQ. ID. NOS. 3, 4, 3 together with 6, or any part thereof may be used for the production of the polypeptides of the present invention.

10 It should be further understood that allelic variations of these DNA and amino acid sequences naturally exist, or may be intentionally introduced using methods known in the art. These variations may be demonstrated by one or more amino acid changes in the overall sequence, such as deletions, substitutions, insertions, inversions or addition of one or more amino acids in said sequence. Such changes may be advantageous in producing or using the polypeptides of the present invention; for example in isolation of MTP or the polypeptides by affinity purification. Amino acid substitutions may be made, for example, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with uncharged polar head groups or nonpolar head groups having similar hydrophilicity values include the following: leucine, isoleucine, valine, glycine, alanine; asparagine, glutamine; serine, threonine; phenylalanine, tyrosine. Other contemplated variations

include salts and esters of the aforementioned polypeptides, as well as precursors of the aforementioned polypeptides; for example, precursors having N-terminal substituents such as methionine, N-formylmethionine and leader sequences. All such variations are included within the scope of the present invention.

Method for detection of nucleic acids

The present invention further concerns a method for detecting a nucleic acid sequence coding for all or part of the high molecular weight subunit of MTP or a related nucleic acid sequence, comprising contacting the nucleic acid sequence with a detectable marker which binds specifically to at least a portion of the nucleic acid sequence, and detecting the marker so bound. The presence of bound marker indicates the presence of the nucleic acid sequence. Preferably, the nucleic acid sequence is a DNA sequence having all or part of the nucleotide sequence substantially as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8, or is complementary thereto.

A DNA sample containing the DNA sequence can be isolated using various methods for DNA isolation which are well-known to those of ordinary skill in the art. For example, a genomic DNA sample may be isolated from tissue by rapidly freezing the tissue from which the DNA is to be isolated, crushing the tissue to produce readily digestible pieces, placing the crushed tissue in a solution of proteinase K and SDS, and incubating the resulting solution until most of the cellular protein is degraded. The genomic DNA is then deproteinized by successive phenol/chloroform/isoamyl alcohol extractions, recovered by ethanol precipitation, and dried and resuspended in buffer.

Also preferred is the method in which the nucleic acid sequence is an RNA sequence. Preferably, the RNA sequence is an mRNA sequence. Additionally preferred is the method in which

the RNA sequence is located in the cells of a tissue sample. An RNA sample containing the RNA sequence may be isolated using various methods for RNA isolation which are well-known to those of ordinary skill in the art. For example, an RNA sample may be
5 isolated from cultured cells by washing the cells free of medium and then lysing the cells by placing them in a 4 M guanidinium solution. The viscosity of the resulting solution is reduced by drawing the lysate through a 20-gauge needle. The RNA is then pelleted through a cesium chloride step gradient, and the
10 supernatant fluid from the gradient carefully removed to allow complete separation of the RNA, found in the pellet, from contaminating DNA and protein.

The detectable marker useful for detecting a nucleic acid sequence coding for all or part of the high molecular weight
15 subunit of MTP or a related nucleic acid sequence, may be a labeled DNA sequence, including a labeled cDNA sequence, having a nucleotide sequence complementary to at least a portion of the DNA sequence coding for all or part of the high molecular weight subunit of MTP.

20 The detectable marker may also be a labeled RNA having a sequence complementary to at least a portion of the DNA sequence coding for all or part of the high molecular weight subunit of MTP.

The detectable markers of the present invention may be
25 labeled with commonly employed radioactive labels, such as ^{32}P and ^{35}S , although other labels such as biotin or mercury may be employed. Various methods well-known to those of ordinary skill in the art may be used to label the detectable markers. For example, DNA sequences and RNA sequences may be labeled
30 with ^{32}P or ^{35}S using the random primer method.

Once a suitable detectable marker has been obtained, various methods well-known to those of ordinary skill in the art may be employed for contacting the detectable marker with the sample of interest. For example, DNA-DNA, RNA-RNA and DNA-

RNA hybridizations may be performed using standard procedures known in the art. In a typical DNA-DNA hybridization procedure for detecting DNA sequences coding for all or part of MTP in genomic DNA, the genomic DNA is first isolated using known
5 methods, and then digested with one or more restriction enzymes. The resulting DNA fragments are separated on agarose gels, denatured in situ, and transferred to membrane filters. After prehybridization to reduce nonspecific hybridization, a radiolabeled nucleic acid probe is hybridized to the immobilized
10 DNA fragments. The membrane is then washed to remove unbound or weakly bound probe, and is then autoradiographed to identify the DNA fragments that have hybridized with the probe.

The presence of bound detectable marker may be detected using various methods well-known to those of ordinary skill in the art. For example, if the detectable marker is radioactively labeled,
15 autoradiography may be employed. Depending on the label employed, other detection methods such as spectrophotometry may also be used.

It should be understood that nucleic acid sequences related
20 to nucleic acid sequences coding for all or part of the high molecular weight subunit of MTP can also be detected using the methods described herein. For example, a DNA probe that has conserved regions of the gene for the high molecular weight subunit of human or bovine MTP can be used to detect and isolate
25 related DNA sequences (e.g., a DNA sequence coding for the high molecular weight subunit of MTP from mice, rats, hamsters, or dogs). All such methods are included within the scope of the present invention.


30 Methods for detecting MTP inhibitors

The present invention further concerns methods for detecting inhibitors of MTP. In particular, the present invention concerns a process for detecting an inhibitor of MTP comprising:
(a) incubating a sample thought to contain an inhibitor of MTP with

detectably labeled lipids in donor particles, acceptor particles and MTP; and (b) measuring the MTP stimulated transfer of the detectably labeled lipids from the donor particles to the acceptor particles. In this assay, an inhibitor would decrease the rate of MTP-stimulated transfer of detectable labeled lipid from donor to acceptor particles. The detection may be carried out by nuclear magnetic resonance (NMR), electron spin resonance (ESR), radiolabeling (which is preferred), fluorescent labeling, and the like. The donor and acceptor particles may be membranes, HDL, low density lipoproteins (LDL), SUV, lipoproteins and the like. HDL and SUV are the preferred donor particles; LDL and SUV are the preferred acceptor particles.


The foregoing procedure was carried out to identify the MTP inhibitor

15 A



which has the name 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-3-oxo-1H-indole hydrochloride (herein referred to as "compound A"). Preparation of compound A is described in U. S. Pat. No. 3,600,393. The foregoing procedure also identified the MTP inhibitor

B



25 which has the name 1-[3-(6-fluoro-1-tetralanyl)methyl]-4-O-methoxyphenyl piperazine (herein referred to as "compound B").

These compounds were identified by the procedures described in the working examples hereinafter.

Methods of treatment

5 The present invention also concerns a novel method for preventing, stabilizing or causing regression of atherosclerosis in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of MTP.

10 The present invention further concerns a novel method for lowering serum lipid levels, such as cholesterol or TG levels, in a mammalian species, which comprises administration of a therapeutically effective amount of an agent which decreases the amount or activity of MTP.

15 The treatment of various other conditions or diseases using agents which decrease the amount or activity of MTP is also contemplated by the present invention. For example, agents which decrease the amount or activity of MTP and therefore decrease serum cholesterol and TG levels, and TG, fatty acid and
20 cholesterol absorption are likely to be useful in treating hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, pancreatitis, hyperglycemia and obesity.

 Various agents which effectively decrease the amount or activity of MTP can be used in practicing the methods of the
25 present invention. MTP inhibitors can be isolated using the screening methodology described hereinabove and in Example 5 hereinbelow. Compounds such as A and B, which are identified as inhibitors of MTP (see Example 6 hereinbelow), are useful in specific embodiments of the foregoing methods of treatment.

30 Antisense molecules may be used to reduce the amount of MTP. [See, Toulme and Helone, Gene 72, 51-8 (1988); Inouye, Gene, 72, 25-34 (1980); and Uhlmann and Peyman, Chemical Reviews 90, 543-584 (1990)]. MTP antisense molecules can be designed based on the foregoing genomic DNA and cDNA,

corresponding 5' and 3' flanking control regions, other flanking sequences, or intron sequences. Such antisense molecules include antisense oligodeoxyribonucleotides, oligoribonucleotides, oligonucleotide analogues, and the like, and may comprise about 15 to 25 bases or more. Such antisense molecules may bind noncovalently or covalently to the DNA or RNA for the high molecular weight subunit of MTP. Such binding could, for example, cleave or facilitate cleavage of MTP DNA or RNA, increase degradation of nuclear or cytoplasmic mRNA, or inhibit transcription, translation, binding of transactivating factors, or pre-mRNA splicing or processing. All of these effects would decrease expression of MTP and thus make the antisense molecules useful in the foregoing methods of treatment.

Potential target sequences for an antisense approach include but are not limited to the DNA or RNA sequence encoding MTP, its 5' and 3' flanking control regions, other flanking sequences, and nonclassic Watson and Crick base pairing sequences used in formation of triplex DNA. Antisense molecules directed against tandem sequences for the high molecular weight subunit of MTP may be advantageous.

Antisense molecules may also contain additional functionalities that increase their stability, activity, transport into and out of cells, and the like. Such additional functionalities may, for example, bind or facilitate binding to target molecules, or cleave or facilitate cleavage of target molecules.

Vectors may be constructed that direct the synthesis of antisense DNA or RNA. In this case, the length of the antisense molecule may be much longer; for example, 400 bp.

30 Demonstration of relationship between MTP and serum cholesterol levels, TG levels, and atherosclerosis

The methods of the present invention for lowering serum cholesterol or TG levels or preventing, stabilizing or causing regression of atherosclerosis are based in part on the discovery by

the inventors that the genetic disease abetalipoproteinemia is caused by a lack of functional MTP. The inventors have demonstrated a gene defect in two abetalipoproteinemic subjects by the following methods.

5

**Assay for TG transfer activity in
abetalipoproteinemic subjects**

A. MTP Assay

10 TG transfer activity was measured as the protein-stimulated rate of TG transfer from donor SUV to acceptor SUV. To prepare donor and acceptor vesicles, the appropriate lipids in chloroform were mixed in a 16 x 125 mm borosilicate glass screw cap tube (Fisher Scientific Co., Pittsburg, PA, Cat. no. 14-933-1A) and then dried under a stream of nitrogen. Two mL 15/40 buffer (15 mM
15 Tris, pH 7.4, 40 mM sodium chloride, 1 mM EDTA, and 0.02% NaH₂PO₄) were added to the dried lipids (or 100 µL per assay, which over is the least volume), a stream of nitrogen was blown over the buffer, then the cap was quickly screwed on to trap a nitrogen atmosphere over the lipid suspension. Lipids in the buffer were
20 bath-sonicated in a Special Ultrasonic Cleaner (Cat. no. G112SP1, Laboratory Supplies Co., Hicksville, NY). The donor and acceptor phosphatidylcholine (PC) (egg L-alpha-phosphatidylcholine, Sigma Chem. Co., St. Louis, MO) was radiolabeled by adding traces of [³H] dipalmitoyl-
25 phosphatidylcholine (phosphatidylcholine L-alpha-dipalmitoyl [2-palmitoyl-9,10, ³H (N)], 33 Ci/mmol, DuPont NEN) to an approximate specific activity of 100 cpm/nmol. Donor vesicles containing 40 nmol egg PC, 0.2 mol% [¹⁴C]TG [mixture of labeled (triolein [carboxyl-¹⁴C]-, about 100 mCi/mmol, DuPont NEN) and
30 unlabeled (triolein, Sigma Chem. Co., St. Louis, MO) triolein for a final specific activity of about 200,000 cpm/nmol], and 7.3 mol% cardiolipin (bovine heart cardiolipin, Sigma Chemical Co.) and acceptor vesicles containing 240 nmol egg PC and 0.2 mol% TG were mixed with 5 mg fatty acid free bovine serum albumin (BSA)

and an aliquot of the MTP samples in 0.7 to 0.9 mL 15/40 buffer and incubated for 1 hour at 37°C. The transfer reaction was terminated by the addition of 0.5 mL DEAE-cellulose suspension (1:1 suspension DE-52, preswollen DEAE-cellulose anion exchange, Fisher, Cat. no. 05720-5 to 15 mM Tris, pH 7.4, 1 mM EDTA, and 0.02% NaN₃). The reaction mixture was agitated for 5 minutes and the DEAE-cellulose with bound donor membranes (the donor membranes contained the negatively charged cardiolipin and bound to the DEAE) were sedimented by low speed centrifugation.

The ¹⁴C-TG and ³H-PC remaining in the supernatant were quantitated by scintillation counting. TG transfer was calculated by comparing the ratio of ¹⁴C-TG (transferred from the donor membranes to the acceptor membranes) to ³H-PC (a marker of acceptor vesicle recovery) present in the supernatant following a transfer reaction to the ratio of total donor ¹⁴C-TG to acceptor [³H]PC in the assay before the transfer reaction. The percentage of ¹⁴C-TG transfer was calculated as follows:

$$\% \text{ TG Transfer} = \frac{(^{14}\text{C-TG}/^{3}\text{H-PC})_{\text{sup}}}{(^{14}\text{C-TG}_{\text{don}}/^{3}\text{H-PC}_{\text{acc}})_{\text{total}}} \times 100\%$$

To calculate the MTP-stimulated rate of TG transfer, the TG transfer rate in the absence of MTP was subtracted from the TG transfer rate in the presence of MTP. First order kinetics was used to calculate total TG transfer.

B. Antibody Production

Anti-88 kDa antibodies were obtained from the University of Cincinnati. The production of anti-88 kDa has been previously described. Wetterau et al., *J. Biol. Chem.* 265, 9800-7 (1990). To help address the specificity of the anti-sera in human intestinal homogenates, affinity purified anti-88 kDa was generated. Eight to 10 mg of purified MTP was dialyzed into 0.1 M MOPS, pH 7.5 and then added to 4 mL Bio Rad Affigel 15 (Bio-Rad, Richmond, CA)

which had been pro washed 3 times with water at 4°C. The MTP was allowed to couple to the matrix at room temperature for two hours and then it was placed at 4°C overnight. The remaining reactive sites on the affigel were blocked by the addition of 0.1 mL 1 M ethanolamine, pH 8.0, per mL gel. Optical density measurements of eluted protein were performed according to the manufacturer's instructions and indicated that more than 90% of the MTP was coupled to the column. The column was washed with 50 mL 10 mM Tris, pH 7.5 followed by 50 mL 100 mM glycine, pH 2.5, followed by 50 mL 10 mM Tris, pH 8.8, followed by 50 mL 100 mM triethylamine, pH 11.5, and finally the column was reequilibrated in 10 mM Tris, pH 7.5.

The antibodies in the antiserum were partially purified by ammonium sulfate precipitation (226 mg ammonium sulfate per mL serum). The pellet was resuspended and dialyzed into 15 mM Tris, pH 7.5, 1 mM EDTA, 0.02% sodium azide, and 150 mM sodium chloride. The partially purified antibodies were slowly applied to the MTP-affigel column over a two-hour period (the antibodies were cycled through the column three times). The column was washed with 100 mL 10 mM Tris, pH 7.5, followed by 100 mL 10 mM Tris, pH 7.5, 500 mM sodium chloride, followed by 50 mL 100 mM glycine, pH 2.5 (this fraction was collected into 5 mL of 1 M Tris, pH 8.0), followed by 10 mM Tris, pH 8.8 until the column was at neutral pH, followed by 50 mL triethylamine pH 11.5 (this fraction was collected into 5 mL 1 M Tris, pH 8.0), and finally the column was reequilibrated with 10 mM Tris, pH 7.5. Antibodies which eluted in the acidic wash were retained and used for immunoblot analysis of protein fractions.

C. Western Blot with anti-88 kDa Antibodies

To confirm the specificity of the antibodies and to detect the 88 kDa component of MTP in tissue homogenates, purified bovine MTP or the fraction to be tested were fractionated by SDS-PAGE [essentially as described by Laemmli, *Nature* 227, 680-5 (1970)]

using a 0.75 mm Hoeffer Scientific Instrument Gel Apparatus (San Francisco, CA). The protein was then transferred to nitrocellulose by Western blotting using a BioRad Trans-blot cell (Bio-Rad, Richmond, CA). The blotting buffer (25 mM Tris, 192 mM glycine, pH 8.3, 20% methanol) was precooled to 4°C. The proteins were transferred for 100 minutes at 250 milliamperes at room temperature. The membranes were blocked 5-10 minutes with blocking buffer (400 µL antifoam, about 10 mg of thimersal, and 200 g nonfat dry milk in 4 liters 50 mM Tris, pH 7.7, 150 mM sodium chloride). An aliquot of the antiserum (1:300 dilution) or affinity purified antibody (1:25 dilution of affinity-purified antibodies) was added and allowed to react overnight at room temperature. Following washing with blocking buffer, the secondary antibody, goat anti-rabbit IgG coupled to horseradish peroxidase (BioRad), was added at a dilution of 1:2000 and allowed to react for 3 hours at room temperature. Following a washing step, the secondary antibody was visualized with developer, 50 mg imidazole, 50 mg 3,3'-diaminobenzidine tetrahydrochloride, and 50 µL H₂O₂ (30% solution) in 50 mL blocking buffer.

D. MTP in Intestinal Biopsies

Intestinal biopsies from fasted control and disease state subjects were frozen and shipped to Bristol-Myers Squibb, Princeton on dry ice. Biopsies were homogenized with a polytron (Polytron PT3000, Brinkmann Instrument, Inc., Westbury, NY) at 1/2 maximal setting. Typically, one biopsy was homogenized in 0.25 mL homogenization buffer (50 mM Tris, pH 7.4, 50 mM KCl, 5 mM EDTA, 5 µg/mL leupeptin, and 2 mM PMSF). An aliquot of the protein was adjusted to 0.7 mL and 1.4% SDS and the protein concentration was measured by the method of Lowry *et al.* [*J. Biol. Chem.* **193**, 265-75 (1951)]. The homogenate was diluted with homogenization buffer to about 1.75 mg protein/mL. In some cases, the protein was already more dilute and was used directly.

To release the soluble proteins from the microsomal fraction, one part deoxycholate solution (0.56%, pH 7.5) was added to 10 parts diluted homogenate with vortexing. The sample was incubated at 4°C for 30 minutes, then centrifuged at 103,000 x g for 60 minutes.
5 The supernatant was removed, diluted 1:1 with 15/40 buffer, and then dialyzed overnight into 15/40 buffer. Aliquots of the treated biopsies were assayed for TG transfer activity and Western blot analysis was used to detect 88 kDa protein. TG transfer activity was expressed as the percentage of donor TG transferred per
10 hour as a function of homogenized intestinal biopsy protein.

E. Results with Abetalipoproteinemic Subjects

To investigate whether there is a relationship between defective MTP and abetalipoproteinemia, MTP activity in duodenal
15 or duodenal-jejunal biopsies was measured from five control subjects and four abetalipoproteinemic subjects having the classic genetically recessive form of abetalipoproteinemia. Intestinal biopsies from the five normal subjects were homogenized and treated with detergent as described hereinabove. TG transfer
20 activity was readily detectable in biopsies from all five subjects (Figure 2).

The TG transfer activity in the biopsies was further characterized. To confirm that TG hydrolysis was not interfering with lipid transfer activity measurements, one subject's acceptor
25 vesicles (which contained the transported lipid) were extracted after the transfer reaction, and the identity of the ¹⁴C-TG was confirmed by thin layer chromatography. All of the ¹⁴C-TG had a mobility identical to that of authentic TG, confirming that intact TG was being transported in the assay.

30 The human MTP was characterized for its heat stability. It was inactivated when heated to 60°C for 5 minutes. The loss of activity demonstrates that the lipid transfer activity being measured was not from an intracellular form of the cholesteryl ester transfer

protein (CETP), which is heat-stable under these conditions. Ihm et al., *J. Biol. Chem.* 257, 4818-27 (1982).

Intestinal biopsies from four abetalipoproteinemic subjects were obtained, homogenized, and TG transfer activity was measured as described herein above. No transfer activity was recovered from the biopsies of any of the four subjects (Figure 3). The lack of detectable TG transfer activity could have been related to an inability to release MTP from the microsomes of the abetalipoproteinemic biopsies by deoxycholate treatment. To test this possibility, the microsomes from one subject were sonicated in addition to being treated with detergent. Bath sonication independently releases TG transfer activity comparable to that of detergent treatment. Even under these conditions, no TG transfer activity was detectable.

The next possibility considered was that the lack of detectable TG transfer activity was related to the inability to detect it in cells which contain large intracellular fat droplets such as those which occur in abetalipoproteinemia. To test this possibility, three controls were run. First, TG transfer activity was measured from a biopsy of a subject with chylomicron retention disease. Subjects with chylomicron retention disease have a defect in the assembly or secretion of chylomicrons and have large fat droplets in their enterocytes, analogous to abetalipoproteinemic subjects. In addition, TG transfer activity was measured from a biopsy taken from an individual who was not fasted prior to the biopsy and from a homozygous hypobetalipoproteinemic subject. Both these subjects also had fat-filled enterocytes. In all three cases, TG transfer activity comparable to that of the normal subjects was found (Figure 4), confirming that the presence of intracellular lipid droplets does not interfere with our ability to recover and detect TG transfer activity.

To establish the biochemical defect responsible for the absence of transfer activity, the soluble proteins following release of MTP from the microsomal fraction of the homogenized biopsy

were analyzed by Western blot analysis with antibodies raised against the 88 kDa component of bovine MTP. When normal (Figure 5) or control (Figure 6) subjects were examined with a polyclonal anti-88 kDa antibody, a band comparable to that of the 88 kDa component of bovine MTP was observed. In addition, additional proteins of increased mobility also cross-reacted with this antibody. To confirm the identity of the 88 kDa component of human MTP, the antibody was affinity-purified on an MTP affinity column. Following this treatment, only the protein of molecular weight comparable to that of the 88 kDa component of bovine MTP was immunoreactive (Figure 7).

Western blot analysis of the soluble proteins following detergent treatment of the microsomes of all five normal subjects and three control subjects demonstrated the presence of the 88 kDa component of MTP (Figures 5 to 7). In contrast, no protein corresponding to the 88 kDa component of bovine MTP was apparent in the abetalipoproteinemic subjects (Figure 8). In addition, a similar analysis was performed with 100 µg protein from the whole intestinal homogenates from two abetalipoproteinemic subjects. Again, no band corresponding to the 88 kDa component of MTP was apparent (Figure 8). As a control, immunoblot analysis with anti-PDI antibodies demonstrated the presence of PDI in the latter two abetalipoproteinemic subjects. These results demonstrate that the biochemical basis for the absence of MTP activity in the abetalipoproteinemic subjects is the marked deficiency or the absence of the 88 kDa component of MTP.

Demonstration of a gene defect in an abetalipoproteinemic subject

Amplification of mRNA and DNA by PCR

Two intestinal biopsies were obtained from the duodenal mucosa of a 39-year-old abetalipoproteinemic patient. Previous analysis demonstrated that neither MTP activity nor the 88 kDa

component of MTP were detectable in intestinal biopsies taken from this subject. Each biopsy weighed 5-10 mg and was stored frozen at -70°C. To isolate total RNA, one frozen biopsy was placed into a microfuge tube containing 0.8 mL of cold RNazol B (CinnaBiotecx labs, Friendswood, Texas). The biopsy was homogenized immediately by polytron (Brinkmann, Westbury, NY) for 6 strokes on setting 10. Chloroform (80 µL) was added and the mixture inverted gently 20 times. After a 5-minute incubation on ice, the mixture was centrifuged at 14,000 rpm in an Eppendorf microfuge 5415 (Brinkmann) for 15 minutes at 4°C. Total RNA was precipitated by adding 350 µL isopropanol to the supernatant. The yield from the biopsy was 20 µg of total RNA, or about 2 µg RNA per mg of tissue (0.2%).

RNA (50 ng) was reverse transcribed into first strand cDNA using 2.5 µM random hexamer primers, 5 mM magnesium chloride, 1 mM each deoxynucleotide triphosphate (dNTP), 1 U/µL RNAsin, 2.5 U/µL Moloney Murine Leukemia Virus reverse transcriptase ((M-MLV-RT), and 1X PCR reaction buffer (Perkin-Elmer-Cetus RNA-PCR kit No. N808-0017). The 20 µL reaction was incubated at room temperature for 10 minutes to anneal the primers, and then at 42°C for 30 minutes to reverse transcribe the RNA. The reaction was terminated by heating to 99°C for 5 minutes and cooling to 5°C. The first strand cDNA was added to a 100 µL PCR containing 0.15 µM forward and reverse primers, 2 mM magnesium chloride, 0.2 mM each dNTP, and 2.5 U Taq polymerase in 1.25X PCR buffer. Amplification was conducted in a Perkin-Elmer GeneAmp PCR System 9600 model thermal cycler for 50 cycles consisting of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 1 minute. The reaction was then incubated at 72°C for 7 minutes. The forward and reverse primers used to amplify the 5' region of the RNA encoding the 88 kDa component of MTP are shown below, 5' to 3'.

2091102

DC21a

- 65 -

Forward Primers		Sequence	SEQ. ID. NO.
5	15F	GGCACTGGATGCAGTTGAGGATTGCT	9
	41F	GGTCAATATGATTCTTCTTGCTGTGC	10
	578F	CCGGAATTCCTACCAGGCTCATCAAGACAAAG	11
	900F	ACGGCCATTCCCATTGTGGGGCAGGT	12
Reverse Primers		Sequence	SEQ. ID. NO.
15	678R	TGACACCCAAGACCTGATTGTTGGGGTC	13
	839R	GCCTGCTTCGGTTGTCTTCAGCTCT	14
	1029R	CGCGGATCCTTCTGACAGCCTCAGCCTTGA	15
20	1588R	GGGAGATCATATCTCTGGAGAGCAGT	16
	2117R	CGCGGATCCAGCATAGGAGTCAAGGTTCTC	17

Shown below are the primer combinations used the PCR product length.

Primer Pair	Product Length (bp)
15F + 678R	664
15F + 839R	825
41F + 1029R	998
578F + 1029R	470
900F + 1588R	689
900F + 2117R	1228

The primer sequences are based on the normal human cDNA encoding the 88 kDa component of MTP. All primers are written 5' to 3'. F refers to the forward primer, and R to the reverse

primer. The underlining identifies restriction sites recognized by Eco RI (primer 578F) or Bam HI (primers 1029R and 2117R), which were incorporated into the 5' end of the primers.

5 Subject genomic DNA was isolated from a second frozen intestinal biopsy. The biopsy was placed into a microfuge tube containing 400 μ L extraction buffer (10 mM Tris.Cl, pH 8.0, 0.1 M EDTA, 0.5% SDS, 20 μ g/mL RNase I) and homogenized immediately. Homogenization was by polytron for 5 strokes at setting 10. Proteinase K was added to a final concentration of 100
10 μ g/ml and the reaction incubated at 50°C for 3 hours. The mixture was swirled periodically.

After cooling the reaction to room temperature, 400 μ L Tris-saturated phenol/chloroform (pH 8.0) was added. The tube was inverted gently for 5 minutes and then centrifuged for 5 minutes at
15 14,000 rpm at room temperature. 2 M sodium chloride (35 μ L) and ethanol (0.7 ml) were added to the supernatant (350 μ L) to precipitate the DNA. The DNA was centrifuged briefly, washed gently with 70% ethanol, dried briefly, and resuspended in 20 μ L of deionized water (dH₂O). The yield of DNA was 20 μ g, or about 2
20 μ g DNA per mg tissue (0.2%).

Genomic DNA (0.5 μ g) was heated to 95°C for 5 minutes and added immediately to a 100 μ L PCR reaction containing 0.15 μ M forward and reverse primers, 2 mM magnesium chloride, 0.2 mM each dNTP, and 2.5 U Taq polymerase in 1.25X PCR buffer
25 (Perkin-Elmer-Cetus). Amplification was conducted in a Perkin-Elmer GeneAmp PCR System 9600 model thermal cycler for 3 cycles consisting of 97°C for 30 seconds, 50°C for 30 seconds, and 72°C for 1 minute. An additional 32 cycles consisting of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 1 minute were
30 run. The reaction was then incubated at 72°C for 7 minutes.

Exon 2 of the gene encodes bases 109-296 of the 88 kDa component of MTP RNA. The primers (SEQ. ID. NOS. 18 and 19) used to amplify exon 2 of the gene encoding the 88 kDa component of MTP from subject genomic DNA are shown below.

<u>Primer Pair</u>	<u>SEQ. ID. NO.</u>
CCCTTACAATGAAAACCTGG	18
GGTACACTTCTCCAAAACTT	19

These primers were designed based on the normal human DNA sequence encoding the 88 kDa component of MTP. The primers are complementary to the introns flanking the 188 bp exon 2 so that the entire exon is amplified in the PCR reaction. The amplification product size, including the primers and flanking intronic regions, is 292 bp long.

B. Sequencing of PCR products

The PCR products obtained from both RNA- and DNA-PCR were electrophoresed on a 1.4% agarose gel in TAE buffer (40 mM Tris-acetate, 1 mM EDTA pH 8.0). The gel was stained for 5 minutes in 0.5 mg/mL ethidium bromide in water, and destained in water for 10 minutes. The DNA was visualized on an ultraviolet light box. The bands containing the desired PCR product were excised with a razor blade, and the DNA was purified by the GeneClean method (Bio 101, La Jolla, CA). The DNA was eluted from the silica matrix in 20 µL of distilled water. Each PCR reaction yielded approximately 1 µg of the desired DNA fragment. A portion of the purified DNA was sequenced directly by Taq polymerase cycle sequencing on an Applied Biosystems, Inc., 373 Automatic Sequencer, as described by Tracy and Mulcahy, Biotechniques, 11, 68 (1991).

The remaining DNA was prepared for cloning into a plasmid vector by producing blunt-ends with T4 DNA polymerase followed by phosphorylation with T4 polynucleotide kinase. DNA (500 ng) was added to a 50 µL reaction mixture containing 20 µM each dNTP, 1 mM ATP, 4.5 units T4 DNA polymerase, 5 units T4 polynucleotide kinase in 50 mM Tris HCl pH 7.5, 10 mM magnesium chloride, 1 mM dithiothreitol, and 50 µg/mL BSA. Incubation was at 37°C for 1 hour. The DNA was then purified from the reaction mixture by GeneClean. The DNA was eluted in 10 µL

**Demonstration of a gene defect in a second
abetalipoproteinemic subject**

A. Methods

Genomic DNA was isolated from blood from a second
5 abetalipoproteinemic subject using Qiagen (Chatsworth, Ca) kit
no. 13343, following the manufacturer's protocol. Like the first
subject, we have previously demonstrated that neither MTP activity
nor the 88 kDa component of MTP could be detected in intestinal
biopsies from this subject. Three hundred µg of this genomic DNA
10 was sent to Stratagene (La Jolla, CA) to be made into a genomic
DNA library in the lambda DASH™ Vector (Stratagene). In
addition, a normal genomic library in the lambda DASH™ vector
was purchased from Stratagene (catalogue no. 943202).

Two million independent recombinant phage plaques from
15 each library were screened for genomic DNA inserts containing
sequences homologous to bovine MTP cDNA. The screening
process was similar to that for the cDNA library screen in Example
1 except that the *E. coli* host strain was PLK 17, hybridization and
wash temperatures were at 60°C, and the wash buffer was 1 X
20 SSC, 0.1% SDS. The probe for the genomic library screen was
the 2.4 kb Eco RI fragment from the bovine cDNA clone no. 22,
32P-labeled exactly as in example 2. Putative positive clones
(about 30 from each library) were rescreened and remained
positive through two additional rounds of hybridization analysis.
25 Following the tertiary screen, single, isolated positive plaques
were excised from the agar plates and deposited into 1 mL of SM
buffer with 50 µL chloroform. Phage titer was amplified for each
phage stock following the "Small-scale liquid cultures" protocol
from Sambrook, et al., *supra*, p 2.67. One hundred µL of the
30 amplified stocks was mixed with 100 µL of prepared PLK 17
plating cells and 100 µL of 10 mM magnesium chloride, 10 mM
calcium chloride and incubated at 37°C for 15 minutes. This
mixture was then used to inoculate 50 mL 2X NZY (Bethesda
Research Laboratories) with 0.2% Casamino Acids (CAA, Fisher

2091102

DC21a

- 70 -

Scientific no. DF0288-01-2) and grown overnight at 37°C. Lambda DNA was isolated from the lysed cultures using the Qiagen kit no. 12543 using Qiagen buffers and protocol.

5 Direct DNA sequencing of the genomic DNA inserts was performed as described in Example 1 using lambda DNA as template. Oligonucleotides of about 20 bases, complementary to human cDNA sequence, were used as primers for sequencing normal or abetalipoproteinemic genomic clones. Characterization and sequencing of abetalipoproteinemic and normal genomic
10 clones were performed in parallel (see Example 9). Intron-exon boundaries were identified by comparing genomic and cDNA sequences. Sequencing primers were designed against Intron sequences 5' and 3' to each exon and used to confirm Intron/exon boundaries by resequencing the boundaries. In addition, the
15 coding sequence of both DNA strands for each exon of at least one abetalipoproteinemic genomic clone was sequenced. DNA sequence analysis of exon 13 of the abetalipoproteinemic subject revealed a C-to-T point mutation at base 1830 of the human cDNA. This base change introduces a stop codon at a site that
20 normally encodes the amino acid residue Arg595.

The nucleotide sequence around base 1830 encodes a Taq I endonuclease restriction site (TCGA) in the normal DNA sequence but not in the abetalipoproteinemic subject's DNA sequence (TTGA). To confirm this nucleotide change and address
25 homozygosity of this allele, Taq I digests were performed on genomic DNA from a normal control, the abetalipoproteinemic subject and both parents of the abetalipoproteinemic subject. Genomic DNA was isolated from blood from a normal control, the abetalipoproteinemic subject and the abetalipoproteinemic
30 subject's mother and father as described above. Ten µg of genomic DNA from each sample was digested with 100 units of Taq I (Bethesda Research Laboratories) in 100 µL 1 X REact buffer no. 2 (Bethesda Research Laboratories) at 65°C for 5 hours. Each digestion reaction was spun at 2,000 rpm in an Ultrafree-MC

10,000 NMWL filter unit (no. UFC3 TGC 00 from Millipore) with a molecular weight cut-off of 10,000, for 30 minutes to reduce the reaction volume to 50 μ L. The restriction digest reactions were then subjected to agarose gel electrophoresis through a 1 % gel in
5 TEA buffer at 20 volts for 16 hours. The agarose gel was stained with ethidium bromide, photographed, and then transferred to a nitrocellulose membrane by the method of Southern. E.M. Southern, *J. Mol. Biol.* **98**, 503-17 (1975).

The probe for the Southern hybridization was a PCR
10 product containing exon 13 and some flanking intron sequences (see SEQ. ID NO.24, below). The PCR was performed using the GeneAmp Kit (Perkin-Elmer, Cetus Industries) components and protocol with 0.3 μ g normal genomic DNA as template and 10
15 picomoles each of the forward and reverse primers in a 100 μ L reaction volume. The reaction mix was incubated at 97°C for two minutes, then subjected to 30 cycles consisting of 94°C for 30 seconds, 45°C for 30 seconds, and 72°C for 1 minute, followed by
20 one 7-minute incubation at 72°C and storage at 4°C. The amplified DNA was subjected to electrophoresis through agarose as in example 1 and the expected 702 bp fragment was excised and eluted from the gel. This exon 13 PCR product was then ³²P-
25 labeled as in example 2 and used as a probe for the Southern hybridization. Hybridization and wash conditions were as in example 2. The blot was exposed to X-ray film at -80°C for 5 days.

B. Results

A human genomic library was generated from DNA isolated from a second abetalipoproteinemic subject. Two million phage were probed with a bovine cDNA probe and thirty phage with
30 human genomic DNA inserts homologous to the bovine MTP cDNA were characterized.

DNA sequence analysis of the genomic DNA inserts from the abetalipoproteinemic subject revealed a C-to-T point mutation at base 1830 in exon 13 of the human MTP gene (exon 13

2091102

DC21a

- 72 -

corresponds to bases 1817 to 1914 of the human cDNA). This C-to-T point mutation changes the normal CGA arginine codon at residue 595 to a TGA translational stop signal, resulting in a 300 amino acid truncation of this protein. This nucleotide change was found on all four independent genomic DNA inserts characterized from this individual.

Shown below is the position of the C-to-T mutation in exon 13 of an abetalipoproteinemic subject. The 302 base DNA sequence of the normal exon 13 with flanking intron sequence is shown. DNA corresponding to the forward (→) and reverse (←) PCR primers used to make the probe for the Southern hybridization are indicated above the appropriate arrows. Horizontal lines represent the intron/exon boundaries. The Taq I recognition sequence is boxed. An asterisk (*) designates base 1830, the site of the C-to-T mutation.

SEQ. ID. NO. 24.

```

20      ATTGGCCTC CTTCTTTC CACTGAGGAT TTTTTTTC AAATTGACT      50
      TGGGAACAG TCATTACAT GAATGTGCG CTTTTTTTT CCTCATCT      100
      TCGAGCAAAA TTGTCCGTCG ATTCTGAG GAAATGGTCG CTCACATTA      150
      TACCA TACN
      TGACCGTTC TCCAGGAGTG GATCTCTTC TGCTACACT GGCTACATAG      200
25      AAGGTATGTA CACCAAAAG AGGTTCTCT TCCATACCC ACACCTTAGC      250
      TCA INTRON
      ATTGCTGGA CTGCTATTAA ATTACAGTA TAGTCTGCA TCAGGTAGTC      300
      CC
      CC
30

```

The normal nucleotide sequence surrounding the C at base 1830 (TCGA) encodes a Taq I restriction site. In this abetalipoproteinemic subject, the sequence at this site is mutated (TTGA). Therefore, Taq I should cut exon 13 at this site in normal DNA, but not in DNA which contains the mutation. There is only one Taq I site in the normal exon 13.

A Southern blot confirms this nucleotide change (Figure 9). The genomic DNA isolated from a control subject, the abetalipoproteinemic subject, and the subject's mother and father was cut to completion with Taq I and probed with sequences from exon 13. The normal DNA is cut by Taq I into two pieces which hybridize to exon 13; the abetalipoproteinemia DNA is not cut with Taq I, evidenced by only one hybridizing band. This result confirms the lack of a Taq I recognition sequence. The DNA from both parents exhibits a mixed pattern, demonstrating the presence of one normal allele and one mutated allele.

C. Analysis

The foregoing results and the conclusions drawn from them can be summarized as follows.

MTP activity and protein are undetectable in the abetalipoproteinemic subjects studied. Mutations in the MTP gene fully explain the lack of protein and activity. Previous results demonstrate that abetalipoproteinemia is a monogenetic disease Kane & Havel, *supra*. From these results, one can conclude that abetalipoproteinemia is caused by a loss of MTP activity.

These results demonstrate that MTP activity is required for the efficient assembly and secretion of lipoprotein particles which contain apolipoprotein B. Loss of MTP activity results in lower serum levels of cholesterol, triglycerides, phospholipids, and cholesterol esters. One can thus conclude that a decrease in the amount of activity of MTP will result in lower serum lipid levels.

Moreover, lower serum lipid levels are associated with prevention, stabilization, or regression of atherosclerosis. As

discused above, loss of the amount or activity of MTP results in lower serum lipid levels. In addition, abetalipoproteinemic subjects lack atherosclerosis. Schaefer, supra; Dische and Porro, Am. J. Med., 49, 568-71 (1970); and Sobrevilla et al., Am. J. Med., 5 37, 821 (1964). One can thus also conclude that inhibition of MTP will result in the prevention, stabilization, or regression of atherosclerosis.

The following examples further illustrate the present invention. These examples are not intended to limit the scope of 10 the present invention, and may provide further understanding of the invention.

Example 1**Isolation and DNA Sequence Analysis of cDNA Clones Encoding the 88 kDa Component of the Bovine MTP**

5 A commercially available bacteriophage lambda gt10/bovine small intestine cDNA library was purchased from Clontech. 1×10^6 independent recombinant phage plaques were screened for the cDNA corresponding to the 88 kDa component of bovine MTP.

10 An *E. coli* bacteria host, strain C600 (Clontech), was prepared for phage infection by growing overnight to saturation at 30°C in 50 mL of Luria Broth (LB = 10 g sodium chloride, 10 g Bacto-Tryptone and 5 g Yeast Extract per liter) supplemented with 0.2% maltose and 10 mM magnesium sulfate. The cells were
15 pelleted by low speed centrifugation, resuspended in 20 mL of 10 mM magnesium sulfate and stored at 4°C. Twenty aliquots each of 50,000 phage and 300 µL of the C600 cells were incubated at 37°C for 15 minutes, mixed with 7 mL LB + 0.7% agarose and plated on 132 mm LB Plates. The plates were incubated for 7-10
20 hours at 37°C until distinct phage plaques appeared, then transferred to 4°C.

Duplicate plaque transfers to nitrocellulose membranes were performed for each plate as follows. A nitrocellulose membrane (Schleicher & Schuell, Keene, NH) was placed directly
25 on the phage for 1 minute (first transfer) or 3 minutes (second transfer). The phage DNA adhering to the membrane was then denatured for 1 minute in 0.5 N sodium hydroxide, 1.5 M sodium chloride, neutralized for 1 minute in 1 M Tris, pH 8.0, 1.5 M sodium chloride, and finally washed for 1 minute in 2 X SSC (1 X SSC =
30 0.15 M sodium chloride, 0.015 M sodium citrate, pH 7.0). The DNA was then permanently fixed onto the nitrocellulose membrane by baking in an 80°C vacuum oven for 2 hours.

The isolation of bovine MTP, including the 88 kDa component, has been previously described. See Wetterau and

Zilversmit, *Chem. Phys. Lipids* **38**, 205-72 (1985); Wetterau et al., *J. Biol. Chem.* **265**, 9800-7 (1990). The sequences of internal peptides of the 88 kDa component were used to design oligonucleotides which would hybridize to cDNA that encodes the protein. See Lathé, R., *J. Mol. Biol.* **183**, 1-12 (1985).

The procedures described herein employed probes having the following DNA sequences (listed 5' to 3'):

Probe	Sequence	SEQ. ID. NO.
2A	CTCTACCAGCGAGTATTAAT	25
37A	ACGTAGGATGTCTTGGACAATGGAGAGCATGTA	26
19A	GATCAGTTGGTTATCATCACCATCAGGACT	27

Probe 2A is a mixture of thirty-two twenty base oligonucleotides, each encoding the amino acid sequence of the peptide from which this probe was designed. Probe 37A is a unique 33 base sequence and probe 19A is a unique thirty-mer. These oligonucleotide sequences encode amino acid sequences that correspond to internal peptides.

Oligonucleotides were obtained from commercial sources as indicated herein or synthesized on a Milligen/Bioscience (Millipore Corp., Bedford, MA) 8700 DNA Synthesizer using beta-cyanoethyl phosphoramidite chemistry. Sequencing primers were desalted on NAP-10 columns (Pharmacia LKB Biotechnologies, Inc., Piscataway, NJ) prior to use. Probes were purified on NENSORB Prep Resin (DuPont Company, NEN Research Products, Boston, MA).

Probe 2A was purchased from Genosys Biotechnologies, Inc. (The Woodlands, Texas) and was labeled by incubating 1 µg of the oligonucleotide in 50 mM Tris-Cl, pH 7.5, 10 mM magnesium chloride, 5 mM dithiothreitol (DTT), 0.1 mM ethylenediaminetetraacetate (EDTA), and 0.1 mM spermidine with 10 units T4 polynucleotide kinase and 120 µCi of gamma labeled ³²P-ATP in a 50 µL reaction volume at 37°C for 30 minutes followed by heat inactivation of the kinase at 68°C for 5 minutes. Unreacted ATP was removed utilizing a G-25 Sephadex spin

column (Boehringer Mannheim Corp., Indianapolis, IN) following the manufacturer's instructions. The labeled oligonucleotide had a specific activity of approximately 2×10^8 dpm/ μ g.

- 5 The nitrocellulose membranes were prehybridized for 2 hours at 37°C in 150 mL of hybridization buffer (6 X SSC, 20 mM NaPO₄, 2 X Denhardt's, 0.1% SDS, and 100 μ g/mL salmon sperm DNA) (See Sambrook *et al.* *supra*, p. B15 for Denhardt's). The hybridization buffer was replaced and the labeled oligonucleotide probe 2A was added and allowed to hybridize overnight at 37°C.
- 10 The membranes were washed in 1 liter of 2 X SSC, 0.1% SDS at 40°C, air-dried, and exposed to Kodak XAR-5 X-ray film for 5 days at -80°C, with a Dupont lightening plus intensifying screen (Dupont, NEN).

- 15 Putative positive clones (40) were rescreened with the same probe through two subsequent rounds of hybridization. Agar plugs corresponding to positive signals on the X-ray films were excised from the original plates and placed in 1 mL SM + 5% CHCl₃ (SM = 5.8 g sodium chloride, 2.0 g magnesium sulfate, 50 mL 1 M Tris-Cl pH 7.5, and 5 mL 2% gelatin per liter). The phage
- 20 were replated by mixing 0.001 μ L of phage stock with 100 μ L C600 cells in 10 mM magnesium sulfate, incubating at 37°C for 15 minutes, adding 3 mL LB + 0.7% agarose and plating onto 82 mm LB plates. After overnight incubation at 37°C followed by 1 hour at 4°C, the phage plaques were transferred to nitrocellulose, and
- 25 reprobbed as above to labeled oligonucleotide probe 2A. Following the tertiary hybridization screen, 16 phage plaques were isolated.

- The inserts of each of the 16 recombinant phage were amplified by PCR using the commercially available lambda gt10
- 30 amplimers (Clontech) and the GeneAmp Kit (Perkin-Elmer, Cetus Industries, Norwalk, CT) following the manufacturer's protocols exactly. The amplified DNA was subjected to electrophoresis through 1.2% agarose gels in Tris-EDTA-Acetate (TEA = 40 mM Tris-Acetate, 1 mM EDTA) buffer, for 2-3 hours at 100 volts. The

agarose gels were then stained in ethidium bromide (EtBr), rinsed in water and photographed. The DNA was then transferred from the gel to a nitrocellulose membrane by the method of Southern. A Southern hybridization was performed using labeled
5 oligonucleotide probe 2A in 50 mL hybridization buffer (above) at 40°C overnight then washing at 45°C, 48°C and 51°C. Two amplified inserts, corresponding to phage no. 64 and no. 76 (Figure 1), hybridized to probe 2A at 51°C in 2 X SSC. Lambda DNA of these 2 clones was prepared following the plate lysate
10 procedure (Sambrook, *et al.*, *supra*, p. 2.118). One-tenth (5 mL of 50ml) of the phage DNA was digested with 20 units of the restriction enzyme Eco RI (New England Biolabs, Beverly, MA) in the manufacturer's buffer at 37°C for 2 hours and subjected to agarose gel electrophoresis. Upon EcoRI cleavage of these
15 phage, no. 64 yielded a 1.0 kb insert fragment and the cDNA from phage no. 76 yielded two EcoRI pieces, of 0.9 kb and 0.4 kb. These bands were excised from the gel.

DNA was eluted from the agarose gel slices by first forcing the gel slices through a 21 gauge needle into 3 mL of T₁₀E₁N₃ (10 mM Tris-Cl pH 7.4, 1 mM EDTA pH 8.0 and 0.3 M sodium chloride) and freezing at -20°C overnight. The samples were then thawed at 37°C for 30 minutes, centrifuged to pellet the agarose, diluted 1:1 with water and passed through an Elu.Tip column (Schleicher & Schuell) following the manufacture's protocol. The DNA
20 samples were then ethanol precipitated, ethanol washed, and resuspended to an approximate concentration of 0.05 pmoles/μL.

The plasmid vector bluescript SK+ (Stratagene) was prepared to receive the cDNA Inserts by digestion with 20 units of the restriction endonuclease Eco RI (New England Biolabs) in the
30 manufacturer's buffer at 37°C for 2 hours, followed by a 30 minute treatment with 1 unit of calf alkaline phosphatase (Boehringer-Mannheim) which is added directly to the Eco RI reaction. This DNA was then electrophoresed through a 1.2% agarose/TEA gel

at 100 volts for 2 hours. The linear plasmid band was excised, eluted and resuspended as above.

cDNA insert fragments were ligated into the prepared bluescript plasmid vector by mixing 0.05 pmole of vector with 0.10
5 pmoles of cDNA insert in 50 mM Tris-Cl pH 7.4, 10 mM magnesium chloride, 1 mM DTT, 1 mM ATP, and 40 units T4 DNA ligase (New England Biolabs). The 10 μ L reaction was incubated at 15°C overnight. The ligation reaction was then mixed with 100
10 μ L of transformation competent *E. coli* cells, strain DH5a (Bethesda Research Laboratories), and the plasmid DNA transformed into the *E. coli* cells following the standard protocol of Sambrook *et al.*, *supra*, p. 1.74. Transformed cells were plated on LB-agar plates containing 100 μ g/mL ampicillin and grown overnight at 37°C.

15 Plasmid DNA was isolated from ampicillin resistant colonies following the alkaline lysis procedure of Birnboim and Doly [*Nucleic Acids Res.* 7, 1513-23 (1979)]. The purified plasmid DNA was digested with Eco RI as above, subjected to agarose gel electrophoresis and analyzed for the generation of the correct size
20 Eco RI cDNA insert fragment. Cells from a unique colony positive for a cDNA insert were used to inoculate 100 mL of LB containing 100 μ g/mL ampicillin and grown to saturation at 37°C. Plasmid DNA was extracted using a Qiagen plasmid isolation kit no. 12143 (Qiagen, Inc., Chatsworth, CA) following the manufacturer's
25 protocol.

Sequencing of cDNA clones was performed with the Applied Biosystems, Inc. (ABI, Foster City, CA) 373 Automated DNA Sequencer utilizing either dye-labeled primers or dye-labeled dideoxynucleotides. Cycle sequencing with dye-labeled
30 primers was performed with Taq Dye Primer Cycle Sequencing Kits (ABI part nos. 401121 and 401122). One μ g of double-stranded DNA was used per reaction. Methods used for cycling and concentration of sequencing samples were as described in the Cycle Sequencing of DNA with Dye Primers manual (ABI part

no. 901482). Alternatively, cycle sequencing with dye-labeled dideoxynucleotides was performed using the Taq Dye Deoxy™ Terminator Cycle Sequencing Kit (ABI part no. 401113). Typically, 1.25 µg of template with 4 pmol of primer was used per reaction.

5 The template and primer concentrations were varied as necessary to optimize sequencing reactions. Cycling of reactions was performed using a Perkin-Elmer Cetus thermal cycler (model 9810) as described in the Taq Dye Deoxy™ Terminator Cycle Sequencing Protocol (ABI part no. 901497).

10 Following the cycle reactions, Centri-Sep™ spin columns (Princeton Separations, Adelphia, NJ) were used to remove excess dye terminators and primers. Spin column eluants were then precipitated and washed as described in the Taq Dye Deoxy™ Terminator Cycle Sequencing Protocol (ABI part no. 15 901497). A 6% acrylamide denaturing gel was prepared as described in the ABI 373A DNA Sequencing System User's Manual. Just prior to running the gel, samples were resuspended in 5 µL of deionized formamide/50 mM EDTA (pH 8.0) 5/1 (v/v). Samples were denatured at 90°C for two minutes, cooled quickly 20 on ice, then loaded onto a pre-run gel (gel was prerun for approximately 15-20 minutes). The gel was run for 12 hours at the following settings: 2500 volts, 40 amps, 30 watts, 40°C. Sequence analysis was performed with ABI 373A DNA Analysis software (version 1.0.2). Final sequence was obtained using ABI 25 DNA Sequence Editor software seqEd™ (version 1.0) ABI, Inc..

The entire 1036 bp insert of clone no. 64 was sequenced. It encoded 936 bp of open reading frame continuing through the 3 prime end of the insert (corresponding to a polypeptide with a molecular weight of at least 34,000). Comparison of the sequence 30 of this clone to available sequence in nucleotide sequence data banks revealed that the first 91 bases at the 5' end of the clone corresponded to the bovine mitochondrial genome. Therefore, the 1036 bp insert of clone no. 64 resulted from the ligation of two independent cDNAs during the construction of this library.

The 400 bp EcoRI fragment of clone no. 76 was sequenced entirely indicating 81 bp of open reading frame followed by 298 bases of 3 prime untranslated sequence and a poly A region.

5 The lambda gt10 bovine small intestine cDNA library was rescreened with an oligonucleotide probe 37A, an exact 33 bp match to the 5' most peptide sequence encoded by clone no. 64. Two positive clones, no. 22 and no. 23 (Figure 1) were isolated through tertiary screens, subcloned and sequenced as for clone no. 64.

10 Clones no. 22 and 23 contained 2.8 kb and 1.7 kb cDNA inserts respectively. The 2.8 kb cDNA insert of clone no. 22 predicted a continuous open reading frame of 835 amino acids between bases 2 and 2506 (corresponding to a 93.2 kDa polypeptide), followed by 298 base of 3' untranslated sequences and a poly A region.

15 The lambda gt10 library was rescreened with probe 19A, an exact match to the sequence of clone no. 22 corresponding to the 5'-most peptide encoded by that clone, and clone no. 2 was isolated as above. DNA sequence analysis of the 1 kb cDNA insert from clone no. 2 indicated it overlapped clone no. 22 and extended the 5' end of the bovine cDNA by 100 bases. A composite of the DNA sequences of clones no. 2 and no. 22 and the predicted translation product is shown in SEQ. ID. NOS. 1 and 3, respectively.

25 In summary, sequencing of bovine small intestine cDNA clones corresponding to the 88 kDa component of MTP yielded 2900 bp of continuous sequence which encodes an open reading frame of 860 amino acids followed by a 298 bp 3' noncoding region and a poly A region. The predicted protein product of this composite sequence is 96.1 kDa.

30

Example 2**DNA Hybridization Analysis of Related Species**

Southern hybridization analysis was performed on DNAs from cow, human, mouse, hamster (Chinese hamster ovary or CHO cells), rat, and dog. 10 µg of each genomic DNA (Clontech) was digested with 140 units of Eco RI (New England Biolabs) in 100 µL 1 X Eco RI buffer (New England Biolabs) at 37°C, overnight. Each digestion reaction was spun at 2,000 rpm in a Ultrafree-MC 10,000 NMWL filter unit (no. UFC3 TGC 00 from Millipore) with a molecular weight cut-off of 10,000, for 30 minutes to reduce the reaction volume to 50 µL. The restriction digest reactions were then subjected to agarose gel electrophoresis through a 0.75% gel in TEA buffer at 80 volts for 3 hours. The agarose gel was stained with ethidium bromide, photographed, and then transferred to a nitrocellulose membrane by the method of Southern.

A Southern hybridization was performed using the 2.4 kb Eco RI fragment from the bovine cDNA clone no. 22 as a probe. Twenty-five ng of the DNA fragment was labeled using the Multiprime DNA Labelling System (Amersham Corp., Arlington Heights, IL) and 50 µCi of ³²P-α-dCTP. Unincorporated ³²P was separated from the labeled probe using a Sephadex G25 spin column as above. The nitrocellulose membranes was prehybridized in 100 mL hybridization buffer (above) at 37°C for 2 hours. The hybridization was performed overnight in 50 mL fresh hybridization buffer at 60°C with 1.2 X 10⁷ dpm denatured probe. The membrane was washed in 500 mL 1 X SSC, 0.1% SDS at 65°C for 1 hour, air-dried, and then exposed to X-ray film at -80°C with an intensifying screen for 4 days. The 2.4 kb Eco RI fragment from bovine clone no. 22 specifically hybridized to at least two DNA bands in every species tested. Therefore, it was concluded that the hybridization conditions established for the bovine cDNA probe allows detection of homologous DNAs from other species, such as human, mouse, hamster, rat and dog.

Example 3**Isolation and DNA Sequence Analysis of cDNA
Clones encoding the 88 kDa Component of Human
MTP****A. Cloning and Sequence Analysis**

To obtain the full coding sequence of the 88 kDa component of human MTP, a human liver cDNA library was screened with a bovine MTP cDNA insert described herein above.

10 The library was obtained from Stratagene. It contained oligo dT primed liver cDNA directionally cloned (EcoRI to XhoI) into the lambda ZAP vector. The probe was obtained by digestion of 10 µg of bovine intestinal clone no. 22 above in universal buffer (Stratagene) with 50 units of EcoRI, electrophoresis at 80-150

15 volts through a gel consisting of 0.9% low melting point agarose (Bethesda Research Laboratories, Gaithersburg, MD), TAE (40 mM Tris acetate, 1 mM EDTA), and 0.5 µg/mL ethidium bromide. The resulting 2.4 Kb fragment was purified by phenol extraction as described in Sambrook *et al.*, *supra*, p. 6.30. The purified

20 fragment was then radiolabelled with a multiprime DNA labelling kit and alpha ³²P dCTP (Amersham) to 10⁹ cpm/µg using the manufacturer's instructions. Unincorporated ³²P was separated from the labeled probe using a Sephadex G-25 spin column as above.

25 10⁸ plaques from the library were screened as follows according to the manufacturer's instructions (Stratagene). *E. coli* bacteria, strain XL 1 Blue (Stratagene), were grown with shaking overnight at 37°C in 50 mL LB broth (Bethesda Research Laboratories) supplemented with 0.2% maltose and 10 mM

30 magnesium sulfate. The cells were sedimented by low speed centrifugation and then resuspended in 10 mM magnesium sulfate to an OD₆₀₀ = 0.5 and stored at 4°C. Phage were diluted to a concentration of 50,000 plaque forming units/25 µL SM buffer. For each plate, 600 µL of bacteria, and 25 µL of phage were mixed

and incubated at 37°C for 15 minutes. Top agar (6.5 mL) consisting of NZY broth (Bethesda Research Laboratories), 0.7% agarose (Bethesda Research Laboratories) preheated to 50°C, was added to the bacteria and phage mixture, and then plated
5 onto a 150 mm NZY plate. The top agar was allowed to solidify and the plates were incubated overnight at 37°C.

The plates were then cooled to 4°C for 2 hours and the plaques were lifted onto nitrocellulose filters. Duplicate lifts were performed in which the alignment of the membranes relative to the
10 plate were recorded by placing needle holes through the filter into the agar plate. The filters were incubated 1 minute in 0.5 N sodium hydroxide, 1.5 M sodium chloride, 1 minute in 1 M Tris, pH 8.0, 3 M sodium chloride, and 1 minute in 2 x SSC. Filters were then baked at 80°C in a vacuum chamber for 2 hours. The filters
15 were incubated for 2 hours at 60°C in 5 mL per filter of hybridization buffer (6 X SSC, 20 mM NaPO₄, 2 X Denhardt's, 0.1% SDS, and 100 µg/mL salmon sperm DNA). The buffer was replaced with an equal volume of hybridization buffer containing the probe at a concentration of 3.5×10^6 cpm per filter and
20 incubated overnight at 60°C. The filters were washed in 1 X SSC, 0.1% SDS first at room temperature and then at 50°C for 2 hours. Autoradiography revealed 56 positives.

A small plug of agarose containing each positive was incubated overnight at 4°C with 1 mL of SM buffer and a drop of
25 chloroform. The positive phage were purified by replating at a low density (approximately 50 - 500 per 100 mm plate), screening and isolating single positive plaques as described above.

When XL1 Blue cells are infected with the ZAP vector (Stratagene) and coinfectd with a helper phage, the bluescript
30 part of the vector is selectively replicated, circularized and packaged into a single stranded phagemid. This phagemid is converted to a double stranded plasmid upon subsequent infection into naive XL1 Blue cells. The cDNA insert of the resultant plasmid can be sequenced directly. Plasmids containing

the positive human liver cDNA inserts were excised in this manner utilizing the helper phage provided by Stratagene according to the manufacturer's directions.

DNA from these clones was purified as follows. A single colony was inoculated into 2 mL of LB and incubated with shaking at 37°C overnight. 1.5 mL of this was centrifuged and resuspended in 50 µL of LB. 300 µL of TENS (1 X TE, 0.1 M sodium hydroxide, 0.5% SDS) was added and vortexed for 5 seconds. 150 µL of 3 M sodium acetate, pH 5.2 was added and vortexed for 5 seconds. The samples were then spun in a microfuge for 10 minutes. The supernatant was recovered, 0.9 mL of ethanol was added and the samples were spun in a microfuge for 10 minutes. The pellet was washed in 70% ethanol, dried, and resuspended in 20 µL of TE (10 mM Tris pH 7.4, 1 mM EDTA pH 8).

The DNA from the clones was characterized as follows. Five µL of the DNA from each clone were digested with 10 units Eco RI, 10 units XhoI, and 10 µg RNase, and then fractionated and visualized by electrophoresis through a 1% agarose, TBE (45 mM Tris-Borate, 1 mM EDTA), 0.5 µg/mL ethidium bromide gel. A Southern blot of the gel was performed as described in Sambrook et al., *supra*, p. 9.41. This Southern blot was probed with a fragment of the bovine cDNA near the 5' end of the coding sequence. This 5' probe was prepared by digesting 25 µg of bovine intestinal clone no. 2 above with 50 units EcoRI and 50 units of NheI, isolating as above the 376 base pair fragment from a 2% low melting point agarose, TBE, 0.5 µg/mL ethidium bromide gel, and radiolabelling as described above. The results are as follows: Clone no. 693, 3.7 kB insert, hybridizes with the 5' probe; Clone no. 754, 1.2 kB insert, hybridizes with the 5' probe; Clone no. 681, 1.8 kB insert, does not hybridize with the 5' probe.

Overnight cultures containing these three clones were grown in 200 mL of LB with 100 µg/mL ampicillin. Large amounts of plasmid were purified using a Qiagen plasmid maxiprep kit

according to the manufacturer's instructions. The sequence of clone no. 693 reveals that it contained two inserts. The 5' 500 bp insert was homologous to haptoglobin and will not be discussed further. This was followed by a mutant XhoI and an EcoRI restriction site (the two sites used in the directional cloning). The 3' insert was the cDNA of interest. It contained some 5' untranslated sequence as indicated by the stop codons in all three reading frames. At bases 48 - 2729 there is an ATG-initiated open reading frame corresponding to 894 amino acids. The deduced amino acid sequence begins

M I L L A V L F L C F I

(SEQ. ID. NO. 28). The stop codon is found at bases 2730 - 2732 followed by a 3' untranslated region of 435 bases and a poly A region. The sequence of clone no. 681 confirmed the 3' 1768 bases of this clone, and clone no. 734 confirmed bases 1 through 442.

B. Tissue Localization of the 88 kDa mRNA

A MultiTissue Northern Blot (Clontech) contained 2 µg per lane of polyA⁺ RNA from human heart, brain, placenta, lung, liver, skeletal muscle, kidney or pancreas. Northern hybridization was performed as for the genomic Southern blot. Prehybridization was in 50 mL hybridization buffer at 37°C for 2 hours followed by an overnight hybridization in 20 mL fresh buffer at 60°C with 5.2 x 10⁷ dpm labeled 2.4 kb Eco RI fragment from the bovine intestinal clone no. 22 as above. The Northern blot was washed in 500 mL 0.2 X SSC, 0.1% SDS at 60°C, 1 hour and subjected to autoradiography at -80°C. After a 20 hour exposure to X-ray film there is a predominant signal in the liver RNA lane at about 4.4 kb and no other detectable hybridization. Therefore, cross hybridization of the 2.4 kb fragment of the bovine cDNA detects a human liver RNA specifically. As liver and intestine are the only two tissues in which significant MTP activity has been reported, the cloning and northern blot analysis support the biochemical localization for MTP. Also, the results of the northern analysis

extend this detection to include DNA:RNA hybrids as well as DNA:DNA interactions.

Example 4

5 Expression of MTP in Human Fibroblast Cell Line

I. Methods

All standard molecular biology protocols were taken from Sambrook, supra, except where indicated below. All restriction enzymes used in this example were obtained from Bethesda Research Laboratories (BRL, Gaithersburg, MD). A 3.2 kb fragment extending from nucleotide -64 to 3135 (relative to the translation start site with A of the translation start site ATG codon designated +1), was constructed from plasmids p754 (bases -64 to 384) and p693 (bases 385 to 3135) as follows. A 448 bp EcoRI-NcoI restriction endonuclease fragment and a 2750 bp NcoI-XhoI restriction endonuclease fragment were excised from p754 and p693, respectively. Following gel purification, the fragments were ligated into EcoRI-XhoI cut plasmid pBluescript-SK to yield plasmid pBS/hMTP. The entire hMTP fragment was isolated from pBS/hMTP by restriction endonuclease digestion with HindIII and XhoI and was subcloned into plasmid pCDNA/Neo (Invitrogen, San Diego, CA) to yield plasmid pCDNA/MTP. This places the full-length hMTP coding sequence under the transcriptional control of the highly active Cytomegalovirus promoter.

Plasmids were transfected into 1508T [J. Biol. Chem. 267, 13229-38 (1992)] transformed human skin fibroblasts by the lipofectin reagent (BRL). Cells were split into 100 mm dishes at a density of 25% of confluency, 24 hours prior to transfection. At the time of transfection, 50 mg of plasmid per 100 mm plate were dissolved in 1.5 mL of serum-free Dulbecco's Modified Eagles Medium (DMEM) and added dropwise to a solution of 120 μ L lipofectin reagent in 1.5 mL of serum free DMEM. After a 15-minute incubation at room temperature, the transfection mixtures were added to the 1508T cultures containing 7 mL of serum free

DMEM. Twenty four hours later, the transfection mixtures were removed and 10 mL of fresh DMEM containing 10% fetal bovine serum was added for an additional 24 hours. Cells were scraped from the dish and washed twice with ice cold phosphate buffered saline (PBS). Cell extracts, MTP activity measurements and Western analyses were carried out as described in the foregoing "Assay for TG transfer activity in Abetalipoproteinemic subjects" herein.

10 II. Results

The cDNA containing the full coding sequence for MTP was subcloned into expression vector pcDNA/Neo, yielding construct pcDNA/MTP. This plasmid was transiently expressed in 1508T transformed human skin fibroblasts [*J. Biol. Chem.* 267, 13229-38 (1992)] by liposome mediated transfection. Forty-eight hours after transfection, TG transfer activity was readily detectable above background levels assayed in extracts from cells transfected with the parent plasmid, pcDNA/Neo. Western blot analysis showed the presence of the the 88 kDa component of MTP in cells transfected with pcDNA/MTP but not in cells transfected with pcDNA/Neo. A comparison of the protein mass and activity in the transfected cells to that found in HepG2 cells suggests that the expressed MTP was efficiently incorporated into an active transfer protein complex with PDI.

25

Example 5

Screen for Identifying Inhibitors of MTP

In this screen, the rate of detectably labeled lipid (for example, NMR, ESR, radio or fluorescently labeled TG, CE, or PC) transfer from donor particles (e.g., donor membranes, vesicles, or lipoproteins) to acceptor particles (e.g., acceptor membranes, vesicles, or lipoproteins) in the presence of MTP is measured. A decrease in the observed transfer rate in the presence of an inhibitor of MTP (e.g., contained in a natural products extract or

known compounds) may be used as an assay to identify and isolate inhibitors of MTP function. A variety of assays could be used for this purpose, for example, the synthetic vesicle assays previously published by Wetterau & Zilversmit, J. Biol. Chem. 259, 10863-6 (1984) or Wetterau et al. J. Biol. Chem. 265, 9800-7 (1990) or the assay outlined hereinabove in the "Assay for TG transfer activity in Abetalipoproteinemic subjects." An example of one such assay is as follows.

A. Substrate Preparation

10 In a typical screen using labeled lipoproteins, labeling of lipoproteins with [3 H]-TG is accomplished by the lipid dispersion procedure described by Morton and Zilversmit [Morton, R.E. et al. J. Biol. Chem. 256, 1992-5 (1981)] using commercially available materials. In this preparation, 375 μ Cl of [3 H] triolein (Triolein, 15 [9,10- 3 H (N)]-, NEN Research Products, cat. no. NET-431), 1.5 mg of egg phosphatidylcholine and 160 μ g of unlabeled triolein in chloroform are mixed and evaporated under a stream of nitrogen to complete dryness. Two mL of 50 mM Tris-HCl, 0.01% Na₂ EDTA, 1 mM dithiothreitol, pH 7.4, is added and the tube 20 flushed with nitrogen. The lipids are resuspended by vortexing and the suspension is then sonicated for two 20-minute intervals in a bath sonicator. The sonicated lipids are added to 75 mL rabbit plasma (Pel-Freez Biologicals, Rogers, AR) with 5.8 mL of 8.2 mM diethyl p-nitrophenyl phosphate (Sigma, Cat. No. D9286) and 0.5 mL of 0.4 M Na₂EDTA, 4% NaN₃. The plasma is then 25 incubated under nitrogen for 16-24 hours at 37°C. Low density lipoproteins (LDL) and high density lipoproteins (HDL) are isolated from the incubation mixture and from control plasma which was not labeled by sequential ultracentrifugation 30 [Schumaker & Pupplon, Methods Enzymology 128, 155-170 (1986)]. Isolated lipoproteins are dialyzed at 4°C against 0.9% sodium chloride, 0.01% Na₂EDTA, and 0.02% NaN₃ and stored at 4°C.

B. Transfer Assay

In a typical 150 μ L assay, transfer activity is determined by measuring the transfer of radiolabeled TG from [3 H]-HDL (5 μ g cholesterol) donor particles to LDL (50 μ g cholesterol) acceptor particles at 37°C for three hours in 15 mM Tris, pH 7.4, 125 mM MOPS, 30 mM Na acetate, 160 mM NaCl, 2.5 mM Na₂ EDTA, 0.02% NaN₃, 0.5% BSA with about 50-200 ng purified MTP in the well of a 96-well plate. The material to be tested (e.g., natural product extracts in an assay compatible solvent such as ethanol, methanol or DMSO (typically, 5 μ L of material in 10% DMSO is added) can be screened by addition to a well prior to incubation. The transfer is terminated with the addition of 10 μ L of freshly prepared, 4°C heparin/MnCl₂ solution (1.0 g heparin, Sigma Cat. No. H3393 187 U/mg, to 13.9 mL, 1.5 M MnCl₂, 0.4% heparin (187 I.U.)/0.1 M MnCl₂) to precipitate the 3 H-TG-LDL acceptor particles and the plate centrifuged at 800 x g. An aliquot of the supernatant from each well containing the [3 H]-TG-HDL donor particles is transferred to scintillation cocktail and the radioactivity quantitated. The enzyme activity is based on the percentage of TG transfer and is calculated by the following equation:

$$\text{Enzyme activity} = 1 - \frac{[\text{H}]\text{-TG recovery (+ MTP)}}{[\text{H}]\text{-TG recovery (- MTP)}} \times 100\%$$

In such an assay, the percent TG transfer will increase with increasing MTP concentration. An inhibitor candidate will decrease the percent TG transfer. A similar assay could be performed with labeled CE or PC.

Example 6

Identification and Demonstration of the Activity of MTP Inhibitors

I. Methods**A. Identification of MTP inhibitors**

Using the method outlined in Example 5, MTP inhibitor compounds A and B were identified. The assay measured the
5 bovine MTP-catalyzed rate of transport of radiolabeled TG from donor HDL to acceptor LDL. In this method, an inhibitor decreases the rate of radiolabeled TG transfer.

The MTP-inhibiting activity of these compounds was confirmed in an independent assay following the procedures
10 outlined in the foregoing "Assay for TG transfer activity in abetalipoproteinemic subjects." That assay measured the bovine MTP-catalyzed transport of radiolabeled TG from donor to acceptor SUV.

B. Cell culture

15 The human hepatoblastoma cell line, HepG2, was obtained from the American Type Culture Collection (Rockville, MD; ATCC accession no. 8065). Cultures were maintained at 37°C in a 5% carbon dioxide atmosphere in T-75 culture flasks with 12 mL of RPMI 1640 medium containing 10% fetal bovine serum (all cell
20 culture media and buffers were obtained from GIBCO Life Technologies, Gaithersburg, MD). Cells were subcultured 1:4 once a week and fed fresh medium 3 times a week.

Experiments to measure the effects of compounds A and B on protein secretion were carried out in 48-well plates. HepG2
25 cells were subcultured 1:2 and allowed to come to confluency at least 24 hours before drug treatment. Before commencement of drug treatment, culture medium was removed, the cells washed once with PBS and 1 mL of fresh medium was added quantitatively. Compound A was added to duplicate wells in 10 µL
30 of dimethylsulfoxide (DMSO) to yield varying compound concentrations. DMSO alone (10 µL) was used as the negative control. (Note: DMSO at this concentration has negligible effect on HepG2 cells.) After a 16-hour incubation under standard cell culture conditions, the plates were centrifuged at 2,500 rpm for 5

minutes at 4°C to sediment any loose cells. The media were diluted with cell culture medium 10 times for the apolipoprotein B (apoB) and human serum albumin (HSA) assays, and 20 times for the apolipoprotein A1 (apoA1) assays. The cells were washed
5 twice with cold PBS, and 0.5 mL of homogenization buffer was then added (0.1 M sodium phosphate, pH 8.0; 0.1% Triton X-100). The cells were homogenized by trituration with a 1 mL micropipettor, and protein was measured using the Coomassie reagent (Pierce Chemical Co, Rockford, IL) as described by the
10 manufacturer.

C. ELISA assays for ApoB and ApoA1 and HSA

The ELISA assays to measure protein mass were of the "sandwich" design. Microtiter plates were coated with a monoclonal antibody (primary antibody), specific for the protein of
15 interest (Biodesigns International, Kennebunkport, ME), followed by the antigen or sample, a polyclonal antibody (secondary antibody) directed to the protein of interest (Biodesigns International), and a third antibody conjugated to alkaline phosphatase directed to the secondary antibody (Sigma
20 Blochemical, St. Louis, MO). The 96-well microtiter plates (Corning no. 25801) were coated overnight at room temperature with 100 µL of diluted monoclonal antibody (final concentrations were 1 µg/mL, 2 µg/mL and 4 µg/mL for anti- apoB, apoA1 and HSA, respectively, in 0.1 M sodium carbonate-sodium bicarbonate, pH
25 9.6 and 0.2 mg/mL sodium azide). Coating was carried out overnight at room temperature. After coating and between each subsequent incubation step, the plates were washed five times with 0.9% sodium chloride with 0.05% Tween 20. Duplicate aliquots (100 µL) of diluted culture media or standard (purified
30 apoB, apoA1 or HSA diluted to 0.3125-320 ng/mL with cell culture medium) were added to wells coated with monoclonal antibody. Following incubation for 1.5 hours at room temperature, the antigen or sample was removed and the wells washed. The secondary antibodies were diluted 1:500 in PBS + 0.05% Tween

20 (Buffer III), then 100 μ L was added to each well and incubated for 1 hour at room temperature. The antibody was removed and the wells were washed. All secondary antibodies were polyclonal antisera raised in goat against the human proteins. A rabbit anti-goat IgG, conjugated to alkaline phosphatase, was diluted 1:1000
5 with Buffer III and 100 μ L was added to each well. Following incubation for 1 hour at room temperature, the antibody was removed and wells washed eight times. The substrate p-nitrophenylphosphate (Sigma Biochemical, St. Louis, MO) was
10 added at 1 mg/mL in 0.05 M NaCarbonate-NaBicarbonate, pH 9.8 + 1 mM magnesium chloride. Following a 45-minute reaction at room temperature, the assay was stopped and the color stabilized with the addition of 100 μ L of 0.1 M Tris, pH 8.0 + 0.1 M EDTA. The microtiter plates were read at 405 nm in a V-Max 96-well plate
15 reader (Molecular Devices, Menlo Park, CA).

After subtraction of background, the standards were plotted on a semi-log graph and logarithmic regression was performed. The equation for the curve was used to calculate the concentration of apoB, apoA1 and HSA. The protein concentration was
20 normalized to total cell protein yielding concentrations with units of ng/mL/mg cell protein. Each drug treatment was performed in duplicate and the results were averaged. The apoB, apoA1, and HSA concentrations for each drug treatment were divided by the corresponding protein concentration in the DMSO control. The
25 results were plotted as a percentage of control versus the drug concentration.

D. Lipid analysis

HepG2 cells were subcultured into 6-well dishes and allowed to come to confluency at least 24 hours before drug
30 treatment. Prior to addition of the drug, culture media were removed, cells washed once with PBS, and 1 mL of fresh medium (RPMI 1640 + 10% FBS) was added quantitatively. Compound A was added to duplicate wells in 10 μ L of DMSO to yield varying compound concentrations. DMSO alone (10 μ L) was used as the

negative control. After a 16-hour incubation under standard cell culture conditions, the media were removed and 1 mL of labeling medium (RPMI 1640; 16.5 mg/mL fatty acid free BSA; 1 mM sodium oleate; 1 mM glycerol; 5 μ Ci/mL 3 H-glycerol (Amersham, Arlington Heights, IL, Catalog no. TRA.244) was added with a second addition of compound A. The cultures were incubated for 2 hours under standard cell culture conditions. Media (1 mL) were removed to 15-mL glass tubes and immediately diluted with 2 mL of ice cold methanol and 1 mL of dH₂O. Cells were washed once with PBS and were processed for total protein measurements as described in section I-B.

Total lipids were extracted from the media and analyzed as follows. After addition of 5.0 mL of chloroform and 0.2 mL of 2% acetic acid, the tubes were vortexed for 1 minute and centrifuged at 2,000 rpm for 5 minutes to separate the aqueous and organic phases. The upper aqueous phase was removed and 3.6 mL of methanol:water (1:1) containing 0.1% acetic acid added. After briefly vortexing, the tubes were centrifuged as before and the aqueous phase again removed. The organic phase was quantitatively transferred to clean 15-mL glass tubes and the solvent evaporated under nitrogen. Dried lipids were dissolved in 0.1 mL of chloroform and 30 μ L of each sample were spotted onto silica gel 60A, 19 channel thin layer chromatography plates (Whatman). 5-10 μ g of TG in 10 μ L of chloroform were added as carrier and the plates were developed in hexane:diisopropyl ether:acetic acid (130:70:4, V/V). After drying, lipid was stained by exposing the plates to iodine. Bands corresponding to TG were scraped into scintillation vials. 0.5 mL of dH₂O and 10 mL of EcoLite (ICN Biomedical) scintillation fluid were added and the samples vortexed vigorously. Raw data was normalized to cell protein and expressed as percent of DMSO control.

II. Results

A. Identification of MTP Inhibitors

The primary screen suggested that compound A inhibited the MTP-catalyzed transport of ^3H -TG from HDL to LDL. The ability of compound A to inhibit MTP-catalyzed lipid transport was confirmed in a second assay which measures the MTP-catalyzed transport of ^3H -TG from donor SUV to acceptor SUV. The IC_{50} for compound A is about $1 \mu\text{M}$ (Figure 10).

B. Inhibition of apoB and TG secretion

Compound A was administered to HepG2 cells in a twofold dilution series ranging from 0.156 to $20 \mu\text{M}$. After a 16-hour incubation under standard cell culture conditions, aliquots of the conditioned media were assayed by ELISA for apoB, apoA1 and HSA. ApoB secretion was inhibited in a dose-responsive manner with an IC_{50} of $5 \mu\text{M}$ (Figure 11). The secretion of apoA1 and HSA was unaffected up to the maximum dose of $20 \mu\text{M}$ confirming that the inhibition was specific for apoB. These data indicate that addition of an MTP inhibitor to a human liver cell line inhibits the secretion of lipoproteins which contain apoB.

HepG2 cells were treated with doses of compound A ranging from $1.25 \mu\text{M}$ - $20 \mu\text{M}$ under conditions identical to those utilized for the apoB, apoA1 and HSA secretion experiment. The intracellular pool of TG was radiolabelled for two hours with ^3H -glycerol in the presence of vehicle or varying doses of compound A. The accumulation of radiolabelled TG in the medium was measured by quantitative extraction, followed by thin layer chromatography analysis and normalization to total cell protein. DMSO alone was used as a control. TG secretion was inhibited by compound A in a dose-dependent manner. The IC_{50} was observed to be about $2.0 \mu\text{M}$, which is similar to the IC_{50} for inhibition of apoB secretion (Figure 12). The data confirm that compound A inhibits the secretion of TG-rich lipoproteins that contain apoB.

The foregoing procedures were repeated with compound B. Compound B inhibits MTP-catalyzed ^3H -TG transport from donor SUV to acceptor SUV. The IC_{50} is about 4 to 6 μM (Figure 13). The secretion of lipoproteins that contain apoB is also inhibited in
5 HepG2 cells by compound B (Figure 14).

Example 7

Inhibition of MTP-catalyzed CE and PC Transport

I. Methods

10 To measure the effect of compound A on bovine MTP-catalyzed transport of CE or PC between membranes, the lipid transfer assay which measures TG transfer between SUV was modified. The composition of the donor vesicles was the same, except 0.25 mol% ^{14}C -CE or ^{14}C -PC replaced the labeled TG.
15 The composition of the acceptor vesicles were the same, except labeled PC and unlabeled TG were not included. Following precipitation of donor vesicles, the percentage of lipid transfer was calculated by comparing the ^{14}C -CE or -PC in the acceptor vesicles in the supernatant following a transfer reaction to the total
20 ^{14}C -CE or -PC in the assay. The labeled lipid in the supernatant in the absence of MTP was subtracted from the labeled lipid in the presence MTP to calculate the MTP-catalyzed lipid transfer from donor SUV to acceptor SUV. The remainder of the assay was essentially as described previously.

25 II. Results

The ability of compound A to inhibit the MTP-catalyzed transport of radiolabeled CE and PC between membranes was also investigated. Compound A inhibited CE transfer in a manner comparable to its inhibition of TG transfer. Compound A inhibited
30 PC transfer, but it was less effective at inhibiting PC transfer than CE and TG transfer. Approximately 40% of the PC transfer was inhibited at concentrations of inhibitor which decreased TG and CE transfer more than 80%.

Example 8**Cloning of bovine MTP - 5' end**

A bovine small intestinal cDNA library, packaged in lambda gt10, was obtained from Clontech (#BL1010A). The library was
 5 diluted in SM to contain 50,000 phage/100 μ L (a 1:100,000 dilution). The diluted phage (100 μ L) were mixed with 300 μ L E. Coli C600 cells (Clontech) and incubated for 15 minutes at 37°C. After adding 7 mL of top agarose, the mixture was poured onto a 150 mm plate containing 75 mL of LB agarose. A total of 25
 10 plates, each containing approximately 5×10^4 phage, were prepared in this manner. The plates were incubated overnight at 37°C.

To isolate phage DNA, 10 mL SM (no gelatin) was added to each plate. The plates were then rocked gently at room
 15 temperature for 2 hours. The eluted phage (approximately 8 mL/plate) were collected and pooled. E. Coli cells were sedimented by centrifugation for 10 minutes at 12,000 X g.

Lambda DNA was isolated from the supernatant using the QIAGEN tip-100 (midi) preparation according to the protocol
 20 supplied by the manufacturer. The purified DNA was resuspended in a total of 200 μ L TE (10 mM Tris.Cl pH 8.0, 1 mM EDTA).

1 μ g lambda phage DNA (approximately 3×10^7 molecules) was added to a 100 μ L PCR reaction containing 2 mM magnesium chloride, 0.2 mM each deoxynucleotide triphosphate,
 25 1.25X buffer, and 2.5 units Taq polymerase (Perkin-Elmer Cetus, kit #N801-0555). The concentration of each primer was 0.15 mM. The sequence of the forward primer (SEQ. ID. NO. 29) was as follows:

41 66
 30 GGTCAATATGATTCTTCTTGCTGTGC.

The forward primer's sequence was based on the human cDNA sequence encoding bases 41 to 66 of the 88 kDa component of MTP. The reverse primer (SEQ. ID. NO. 30) had the following sequence:

658 636 (bovine)
807 785 (human)

GCCTCGATACTATTTTGCCTGCT

5 The reverse primer's sequence was based on the known bovine cDNA sequence encoding the 88 kDa component of MTP and hybridizes from base 658 to 636 of the bovine cDNA, which correspond to bases 807-785 of the human cDNA.

10 PCR-amplification was conducted in a Perkin-Elmer thermal cycler, model 9600. After a two-minute incubation at 97°C, the reaction was cycled at 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for one minute for 35 cycles. A final incubation at 72°C for 7 minutes was performed.

15 The PCR product was electrophoresed on a 1% agarose gel in TAE buffer as described previously. The yield of the desired 766 base pair fragment was approximately 2 µg. The DNA was excised from the gel, purified using GeneClean (Bio101 La Jolla, CA), blunt-ended, cloned into pUC 18-Sma1 (Pharmacia), and sequenced as described previously.

20 The new sequence obtained from the bovine cDNA encoding the 5' region of the 88 kDa component of MTP is shown in SEQ. ID. NO. 5. The sequence adds 83 bases to the 5' end of the bovine cDNA reported previously.

25 **Example 2**

Sequencing of human genomic DNA for the 88 kDa component of MTP

30 Sequencing of human genomic DNA was carried out by the procedures described in "Demonstration of a gene defect in a second abetalipoproteinemic subject" and in Example 1. The result of this procedure is the human genomic sequence SEQ. ID. NO. 8.

What is Claimed is:

1. An isolated nucleic acid molecule comprising a nucleic acid sequence coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, wherein
5 the nucleic acid sequence coding for part of the high molecular weight subunit of microsomal triglyceride transfer protein is at least about 15 sequential nucleotides in length.
- 10 2. The nucleic acid molecule according to Claim 1 which is a DNA molecule and wherein the nucleic acid sequence is a DNA sequence.
- 15 3. The DNA molecule according to Claim 2 wherein the DNA sequence has the nucleotide sequence shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8.
- 20 4. The DNA molecule according to Claim 2 wherein the DNA sequence has part of the nucleotide sequence shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8, wherein the DNA sequence coding for part
25 of the high molecular weight subunit of microsomal triglyceride transfer protein is at least about 15 sequential nucleotides in length.
- 30 5. A DNA molecule having a DNA sequence which is complementary to the DNA sequence according to Claim 2.
6. A DNA molecule having a DNA sequence which is complementary to the DNA sequence according to Claim 3.

7. A DNA molecule having a DNA sequence which is complementary to the DNA sequence according to Claim 4.

5 8. An expression vector comprising a DNA sequence coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein; wherein the DNA sequence coding for part of the high molecular weight subunit of microsomal triglyceride transfer protein is at least about 15 sequential nucleotides in length.

10 9. The expression vector according to Claim 8 wherein the DNA sequence coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein has the nucleotide sequence as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1
15 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8.

20 10. The expression vector according to Claim 8 wherein the DNA sequence coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein has part of the nucleotide sequence as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8, wherein the DNA sequence coding for part of the high molecular
25 weight subunit of microsomal triglyceride transfer protein is at least about 15 sequential nucleotides in length.

30 11. A prokaryotic or eukaryotic host cell comprising the expression vector according to Claim 8.

12. A prokaryotic or eukaryotic host cell comprising the expression vector according to Claim 9.

13. A prokaryotic or eukaryotic host cell comprising the expression vector according to Claim 10.

5 14. A method for producing a polypeptide molecule having all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, which comprises culturing a host cell according to Claim 11 under conditions permitting expression of the polypeptide.

10 15. A method for producing a polypeptide molecule having all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, which comprises culturing a host cell according to Claim 12 under conditions permitting expression of the polypeptide.

15 16. A method for producing a polypeptide molecule having all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, which comprises culturing a host cell according to Claim 13 under conditions permitting
20 expression of the polypeptide.

17. A method for detecting a nucleic acid sequence coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein or a related nucleic acid
25 sequence, which comprises:
 (a) contacting the nucleic acid sequence with a detectable marker which binds specifically to at least part of the nucleic acid sequence, and
 (b) detecting the marker so bound;
30 wherein the presence of bound marker indicates the presence of the nucleic acid sequence.

18. The method according to Claim 17 wherein the DNA sequence has the nucleotide sequence as shown in SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, or the first 108 bases of 2 together with 7 and 8, or a part of any thereof of at least 15 sequential nucleotides in length.

19. The method according to Claim 17 wherein the detectable marker is a nucleotide sequence of at least about 15 nucleotides in length complementary to at least a portion of the nucleic acid sequence coding for the high molecular weight subunit of microsomal triglyceride transfer protein.

20. The method according to Claim 19 wherein the nucleotide sequence is selected from the group consisting of a genomic DNA sequence, a cDNA sequence, an RNA sequence, a sense RNA sequence or an antisense RNA sequence.

21. The method according to Claim 17 wherein the detectable marker is labelled with a radiolabel and the detecting step is carried out by autoradiography.

22. An isolated polypeptide molecule comprising at least five sequential amino acids of the high molecular weight subunit of microsomal triglyceride transfer protein.

23. The isolated polypeptide molecule of Claim 22 encoded by all or part of SEQ. ID. NO. 2.

24. The isolated polypeptide molecule of Claim 22 encoded by part of SEQ. ID. NO. 1.

25. The polypeptide molecule according to Claim 22 having the amino acid sequence as shown in SEQ. ID. NOS. 3, 4, or 3 together with 6.

5 26. The polypeptide molecule according to Claim 22 having part of the amino acid sequence as shown in SEQ. ID. NOS. 3, 4, or 3 together with 6.

10 27. A method for detecting an inhibitor of microsomal triglyceride transfer protein comprising:
 (a) incubating a sample thought to contain an inhibitor of microsomal triglyceride transfer with detectably labeled lipids in donor particles, acceptor particles and microsomal triglyceride transfer protein; and
.15 (b) measuring the transfer of the detectably labeled lipid from the donor particles to the acceptor particles promoted by the microsomal triglyceride transfer protein;

20 wherein the inhibitor will decrease the rate of transfer of detectably labeled lipid from donor particles to acceptor particles.

25 28. A method for preventing, stabilizing or causing regression of atherosclerosis in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein.

30 29. A method for decreasing serum lipid levels in a mammalian species, which comprises administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein.

2091102

DC21a


- 104 -

30. The method of Claim 29, wherein the lipid is selected from one or more of cholesterol, triglyceride, cholesteryl ester, and phosphatidylcholine.
- 5 31. A method for preventing or treating pancreatitis in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein.
- 10 32. A method for preventing or treating obesity in a mammalian species comprising administration of a therapeutically effective amount of an agent which decreases the amount or activity of microsomal triglyceride transfer protein.
-

2091102


Figure 1

BOVINE cDNA CLONES




209110J

Figure 2




2091102

Figure 3



2091102

Figure 4




2091102

Figure 5




2091102

Figure 6




2091102

Figure 7




2091102

Figure 8




2091102

Figure 9




2091102

Figure 10




2091102

Figure 11




2091102

Figure 12



2091102

Figure 13



2091102

Figure 14

